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BACKGROUND—Multiple laboratory tests are used to diagnose and manage patients with
diabetes mellitus. The quality of the scientiﬁc evidence supporting the use of these tests varies
substantially.
APPROACH—An expert committee compiled evidence-based recommendations for the use of
laboratorytestingforpatientswithdiabetes.Anewsystemwasdevelopedtogradetheoverallquality
of the evidence and the strength of the recommendations. Draft guidelines were posted on the
Internetandpresentedatthe2007ArnoldO.BeckmanConference.Thedocumentwasmodiﬁedin
responsetooralandwrittencomments,andareviseddraftwaspostedin2010andagainmodiﬁedin
response to written comments. The National Academy of Clinical Biochemistry and the Evidence-
Based Laboratory Medicine Committee of the American Association for Clinical Chemistry jointly
reviewedtheguidelines,whichwereacceptedafterrevisionsbytheProfessionalPracticeCommittee
and subsequently approved by the Executive Committee of the American Diabetes Association.
CONTENT—In addition to long-standing criteria based on measurement of plasma glucose,
diabetes can be diagnosed by demonstrating increased blood hemoglobin A1c (HbA1c) concen-
trations. Monitoring of glycemic control is performed by self-monitoring of plasma or blood
glucose with meters and by laboratory analysis of HbA1c. The potential roles of noninvasive
glucosemonitoring,genetictesting,andmeasurementofautoantibodies,urinealbumin,insulin,
proinsulin, C-peptide, and other analytes are addressed.
SUMMARY—The guidelines provide speciﬁc recommendations that are based on published
data or derived from expert consensus. Several analytes have minimal clinical value at present,
and their measurement is not recommended.
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D
iabetes mellitus is a group of met-
abolic disorders of carbohydrate
metabolism in which glucose is
underutilized and overproduced, causing
hyperglycemia. The disease is classiﬁed
into several categories. The revised clas-
siﬁcation, published in 1997 (1), is pre-
sented in Table 1. Type 1 diabetes
mellitus, formerly known as insulin-
dependent diabetes mellitus (IDDM) or
juvenile-onset diabetes mellitus, is usu-
ally caused by autoimmune destruction
of the pancreatic islet b-cells, rendering
the pancreas unable to synthesize and se-
creteinsulin(2).Type2diabetesmellitus,
formerly known as non-IDDM or adult-
onset diabetes, is caused by a combina-
tion of insulin resistance and inadequate
insulin secretion (3,4). Gestational diabe-
tesmellitus(GDM),whichresemblestype
2d i a b e t e sm o r et h a nt y p e1 ,d e v e l o p s
during approximately 7% (range, 5%–
15%) of pregnancies, usually remits after
delivery, and constitutes a major risk fac-
tor for thedevelopmentof type 2 diabetes
later in life. Other types of diabetes are
rare. Type 2 is the most common form,
accounting for 85%–95% of diabetes in
developed countries. Some patients can-
not be clearly classiﬁed as type 1 or type 2
diabetes (5).
Diabetes is a common disease. The
current worldwide prevalence is esti-
mated to be approximately 250 x 10
6,
and it is expected to reach 380 x 10
6 by
2025 (6). The prevalence of diabetes
[based on fasting plasma glucose (FPG)
results] in U.S. adults in 1999–2002 was
9.3%, of which 30% of the cases were un-
diagnosed (7). The most recent data,
which were derived from the 2005–
2006 National Health and Nutrition Ex-
amination Survey (NHANES) with both
FPG and 2-h oral glucose tolerance test
(OGTT) results, show a prevalence of di-
abetes in U.S. persons $20 years old of
12.9% (approximately 40 x 10
6)( 8 ) .O f
theseindividuals,40%(approximately16
million)are undiagnosed. The prevalence
of diabetes has also increased in other
parts of the world. For example, recent
estimates suggest 110 x 10
6 diabetic indi-
viduals in Asia in 2007 (9), but the true
number is likely to be substantially
greater, because China alone was thought
to have 92.4 x 10
6 adults with diabetes in
2008 (10).
The worldwide costs of diabetes were
approximately $232 billion in 2007 and
are likely to be $302 billion by 2025 (6).
In 2007, the costs of diabetes in the U.S.
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POSITION STATEMENTwere estimated to be $174 billion (11).
The mean annual per capita healthcare
costs for an individual with diabetes are
approximately 2.3-fold higher than those
for individuals who do not have diabetes
(11). Similarly, diabetes in the U.K. ac-
counts for roughly 10% of the National
Health Service budget (equivalent in
2008 to £9 billion/year). The high costs
ofdiabetesareattributabletocareforboth
acute conditions (such as hypoglycemia
and ketoacidosis) and debilitating compli-
cations(12).Thelatterincludebothmicro-
vascular complications—predominantly
retinopathy,nephropathy,andneuropathy—
andmacrovascularcomplications,partic-
ularly stroke and coronary artery disease.
Together, they make diabetes the fourth
most common cause of death in the de-
velopedworld(13).About3.8x10
6peo-
ple worldwide were estimated to have
died from diabetes-related causes in 2007
(6).
The National Academy of Clinical
Biochemistry (NACB) issued its “Guide-
lines and Recommendations for Labora-
tory Analysis in the Diagnosis and
Management of Diabetes Mellitus” in
2002 (14). These recommendations
w e r er e v i e w e da n du p d a t e dw i t ha n
evidence-based approach, especially in key
areas in which new evidence has emerged
sincethe2002publication.Theprocessof
updating guideline recommendations fol-
lowed the standard operating procedures
for preparing, publishing, and editing
NACB laboratory medicine practice
guidelines, and the key steps are detailed
in the Supplementary Data that accom-
panies this special report. A new system
was developed to grade both the overall
quality of the evidence (Table 2) and the
strength of recommendations (Table 3).
This guideline focuses primarily on
the laboratory aspects of testing in di-
abetes. It does not address any issues
related to the clinical management of
diabetes, which are already covered in
the American Diabetes Association (ADA)
guidelines. The NACB guideline intends
to supplement the ADA guidelines in
order to avoid duplication or repetition
of information. Therefore, it focuses on
practical aspects of care to assist with
decisions related to the use or interpreta-
tion of laboratory tests while screening,
diagnosing, or monitoring patients with
diabetes. Additional details concerning
the scope, purpose, key topics, and tar-
gets of this guideline are described in the
accompanying Supplementary Data.
To facilitate comprehension and as-
sistthereader,wedivideeachanalyteinto
several headings and subheadings (in
parentheses), which are as follows: use
(diagnosis, screening, monitoring, and
prognosis); rationale (diagnosis and
screening);analyticalconsiderations(pre-
analytical, including reference intervals;
and analytical, such as methods); inter-
pretation (including frequency of mea-
surement and turnaround time); and,
where applicable, emerging considera-
tions, which alert the reader to ongoing
studies and potential future aspects rele-
vant to that analyte.
GLUCOSE
1. Use
A. Diagnosis/screening. The diagnosis
of diabetes is established by identifying
the presence of hyperglycemia. For many
years the only method recommended for
diagnosis was a direct demonstration of
hyperglycemia by measuring increased
glucose concentrations in the plasma
(15,16). In 1979, a set of criteria based
on the distribution of glucose concentra-
tions in high-risk populations was estab-
lished to standardize the diagnosis (15).
These recommendations were endorsed
bytheWHO(16).In1997,thediagnostic
criteria were modiﬁed (1) to better iden-
tify individuals at risk of retinopathy and
nephropathy (17,18). The revised criteria
Table 2—Rating scale for the quality of
evidence
High: Further research is very unlikely to
change our conﬁdence in the estimate of
effect. The body of evidence comes from
high-level individual studies that are
sufﬁciently powered and provide precise,
consistent, and directly applicable results in
a relevant population.
Moderate: Further research is likely to have an
important impact on our conﬁdence in the
estimate of effect and may change the
estimate and the recommendation. The
body of evidence comes from high-/
moderate-level individual studies that are
sufﬁcient to determine effects, but the
strength of the evidence is limited by the
number, quality, or consistency of the
included studies; generalizability of results
to routine practice; or indirect nature of the
evidence.
Low: Further research is very likely to have an
important impact on our conﬁdence in the
estimate of effect and is likely to change the
estimate and the recommendation. The
body of evidence is of low level and comes
from studies with serious design ﬂaws, or
evidence is indirect.
Very low: Any estimate of effect is very
uncertain. Recommendation may change
when higher-quality evidence becomes
available. Evidence is insufﬁcient to assess
the effects on health outcomes because of
limited number or power of studies,
important ﬂaws in their design or conduct,
gaps in the chain of evidence, or lack of
information.
Table 1—Classiﬁcation of diabetes
mellitus
a
I. Type 1 diabetes
A. Immune-mediated
B. Idiopathic
II. Type 2 diabetes
III. Other speciﬁct y p e s
A. Genetic defects of b-cell function
B. Genetic defects in insulin action
C. Diseases of the exocrine pancreas
D. Endocrinopathies
E. Drug- or chemical-induced
F. Infections
G. Uncommon forms of immune-mediated
diabetes
H. Other genetic syndromes sometimes
associated with diabetes
IV. GDM
aFrom the ADA (378). RECOMMENDATION: WHEN GLUCOSE IS
USED TO ESTABLISH THE DIAGNOSIS
OF DIABETES, IT SHOULD BE MEASURED IN
VENOUS PLASMA
A( h i g h ) .
RECOMMENDATION: WHEN GLUCOSE IS
USED FOR SCREENING OF HIGH-RISK
INDIVIDUALS, IT SHOULD BE MEASURED
IN VENOUS PLASMA
B (moderate).
RECOMMENDATION: PLASMA GLUCOSE
SHOULD BE MEASURED IN AN
ACCREDITED LABORATORY WHEN USED
FOR DIAGNOSIS OF OR SCREENING FOR
DIABETES
Good Practice Point (GPP).
RECOMMENDATION: OUTCOME STUDIES
ARE NEEDED TO DETERMINE THE
EFFECTIVENESS OF SCREENING
C (moderate).
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Position Statementcomprised:1)anFPGvalue$7.0mmol/L
(126 mg/dL); 2) a 2-h postload glucose
concentration $11.1 mmol/L (200 mg/dL)
during an OGTT; or 3) symptoms of di-
abetes and a casual (i.e., regardless of the
time of the preceding meal) plasma
glucose concentration $11.1 mmol/L
(200 mg/dL) (Table 4) (1). If any one of
these three criteria ismet, conﬁrmationby
repeat testing on a subsequent day is nec-
essary to establish the diagnosis [note that
repeat testing is not required for patients
who have unequivocal hyperglycemia,
i.e., .11.1 mmol/L (200 mg/dL) with
symptoms consistent with hyperglyce-
mia]. The WHO and the International Di-
abetes Federation (IDF) recommend
either an FPG test or a 2-h postload glu-
cose test that uses the same cutoffs as the
ADA (19) (Table 5). In 2009, the Interna-
tional Expert Committee (20), which
comprised members appointed by the
ADA, the European Association for the
Study of Diabetes, and the IDF, recom-
mended that diabetes be diagnosed
by measurement of hemoglobin A1c
(HbA1c), which reﬂects long-term blood
glucose concentrations (see HbA1c section
below). The ADA (21) and the WHO have
endorsedtheuseofHbA1cfordiagnosisof
diabetes.
Testing to detect type 2 diabetes in
asymptomatic people, previously contro-
versial, is now recommended for those at
risk of developing the disease (21,22).
The ADA proposes that all asymptomatic
people $45 years of age be screened in a
healthcare setting. An HbA1c,FP G,or2-h
OGTT evaluation is appropriate for
screening (21). The IDF recommends
that the health service in each country de-
cide whether to implement screening for
diabetes(23).FPGisthesuggestedtest.In
contrast, the International Expert Com-
mittee and the ADA have recommended
that HbA1c can be used for screening for
diabetes(20,21,24)(seesectiononHbA1c
Table 4—Criteria for the diagnosis of
diabetes
a
Any one of the following is diagnostic:
1. HbA1c $6.5% (48 mmol/mol)
b
OR
2. FPG $7.0 mmol/L (126 mg/dL)
c
OR
3. 2-h Plasma glucose $11.1 mmol/L
(200 mg/dL) during an OGTT
d
OR
4. Symptoms of hyperglycemia and casual
plasma glucose $11.1 mmol/L
(200 mg/dL)
e
aIn the absence of unequivocal hyperglycemia, these
criteria should be conﬁrmed by repeat testing. From
the ADA (378).
bThe test should be performed in
a laboratory that is NGSP certiﬁed and standardized
to the DCCT assay. Point-of-care assays should not
be used for diagnosis.
cFasting is deﬁned as no ca-
loric intake for at least 8 h.
dThe OGTT should be
performed as described by the WHO, with a glucose
load containing the equivalent of 75 g of anhydrous
glucose dissolved in water.
e“Casual” is deﬁned as
anytimeofdaywithoutregardtotimesinceprevious
meal. The classic symptoms of hyperglycemia in-
clude polyuria, polydipsia, and unexplained weight
loss.
Table 3—Grading the strength of recommendations
A. The NACB strongly recommends adoption
Strong recommendations for adoption are made when
c There is high-quality evidence and strong or very strong agreement of experts that the
intervention improves important health outcomes and that beneﬁts substantially
outweigh harms; or
c There is moderate-quality evidence and strong or very strong agreement of experts that
the intervention improves important health outcomes and that beneﬁts substantially
outweigh harms.
Strong recommendations against adoption are made when
c There is high-quality evidence and strong or very strong agreement of experts that the
intervention is ineffective or that beneﬁts are closely balanced with harms, or that harms
clearly outweigh beneﬁts; or
c There is moderate-quality evidence and strong or very strong agreement of experts that
the intervention is ineffective or that beneﬁts are closely balanced with harms, or that
harms outweigh beneﬁts.
B. The NACB recommends adoption
Recommendations for adoption are made when
c There is moderate-quality evidence and level of agreement of experts that the
intervention improves important health outcomes and that beneﬁts outweigh harms; or
c There is low-quality evidence but strong or very strong agreement and high level of
conﬁdenceofexpertsthattheinterventionimprovesimportanthealthoutcomesandthat
beneﬁts outweigh harms; or
c There is very low–quality evidence but very strong agreement and very high level of
conﬁdenceofexpertsthattheinterventionimprovesimportanthealthoutcomesandthat
beneﬁts outweigh harms.
Recommendations against adoption are made when
c There is moderate-quality evidence and level of agreement of experts that the intervention is
ineffectiveorthatbeneﬁtsarecloselybalancedwithharms,orthatharmsoutweighbeneﬁts;or
c There is low-quality evidence but strong or very strong agreement and high level of
conﬁdence of experts that the intervention is ineffective or that beneﬁts are closely
balanced with harms, or that harms outweigh beneﬁts; or
c There is very low–quality evidence but very strong agreement and very high levels of
conﬁdence of experts that the intervention is ineffective or that beneﬁts are closely
balanced with harms, or that harms outweigh beneﬁts.
C. The NACB concludes that there is insufﬁcient information to make a recommendation
Grade C is applied in the following circumstances:
c Evidence is lacking or scarce or of very low quality, the balance of beneﬁts and harms
cannot be determined, and there is no or very low level of agreement of experts for or
against adoption of the recommendation.
c At any level of evidence—particularly if the evidence is heterogeneous or inconsistent,
indirect, or inconclusive—if there is no agreement of experts for or against adoption of
the recommendation.
GPP. The NACB recommends it as a good practice point
GPPs are recommendations mostly driven by expert consensus and professional agreement
and are based on the information listed below and/or professional experience, or widely
accepted standards of best practice. This category applies predominantly to technical (e.g.,
preanalytical, analytical, postanalytical), organizational, economic, or quality-management
aspectsoflaboratorypractice.Inthesecases,evidenceoftencomesfromobservationalstudies,
audit reports, case series or case studies, nonsystematic reviews, guidance or technical
documents, non–evidence-basedguidelines,personalopinions,expertconsensus,or position
statements. Recommendations are often based on empirical data, usual practice, quality
requirements, and standards set by professional or legislative authorities or accreditation
bodies, and so forth.
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Sacks and Associatesbelow). If an FPG result is ,5.6 mmol/L
(100 mg/dL) and/or a 2-h plasma glucose
concentration is ,7.8 mmol/L (140
mg/dL), testing should be repeated at 3-
year intervals. Screening should be consid-
eredatayoungerageorbecarriedoutmore
frequently in individuals who are over-
weight (BMI $25 kg/m
2)o ro b e s ea n d
who have a least one additional risk factor
for diabetes [see (21) for conditions asso-
ciated with increased risk]. Because of the
increasing prevalence of type 2 diabetes in
children, screening of children is now ad-
vocated(25).Startingatage10years(orat
the onset of puberty if puberty occurs at a
youngerage),testingshouldbeperformed
every 3 years in overweight individuals
who have two other risk factors—namely,
family history, a race/ethnicity recognized
toincrease risk, signs of insulin resistance,
andamaternalhistoryofdiabetesorGDM
during the child’s gestation (25). Despite
these recommendations and the demon-
stration that interventions can delay and
sometimes prevent the onset of type 2 di-
abetes in individuals with impaired glu-
cose tolerance (26,27), there is as yet no
published evidence that treatment based
on screening has an effect on long-term
complications. In addition, the published
literature lacks consensus as to which
screening procedure (FPG, OGTT, and/
or HbA1c)i st h em o s ta p p r o p r i a t e
(20,28–30). On the basis of an evaluation
of NHANES III data, a strategy has been
proposedtouseFPGtoscreenwhites$40
years and other populations $30 years of
age (31). The cost-effectiveness of screen-
ing for type 2 diabeteshas been estimated.
The incremental cost of screening all per-
sons $25 years of age has been estimated
to be $236,449 per life-year gained
and $56,649 per quality-adjusted life-
year (QALY) gained (32). Interestingly,
screening was more cost-effective at ages
younger than the 45 years currently
recommended. In contrast, screening tar-
geted to individuals with hypertension
reduces the QALY from $360,966 to
$34,375, with ages between 55 and 75
years being the most cost-effective (33).
Modeling run on 1 x 10
6 individuals sug-
gests considerable uncertainty as to
whether screening for diabetes would be
cost-effective (34). By contrast, the results
ofamorerecentmodelingstudyimplythat
screening commencing at 30 or 45 years is
highly cost-effective (,$11,000 per QALY
gained) (35). Long-term outcome studies
arenecessarytoprovideevidencetoresolve
the question of the efﬁcacy of diabetes
screening (36).
In 2003, the ADA lowered the thresh-
old for “normal” FPG from ,6.1 mmol/L
(110mg/dL)to,5.6mmol/L(100mg/dL)
(37).Thischangehasbeencontentiousand
has not been accepted by all organizations
(19,38).The rationale isbased ondata that
individuals with FPG values between 5.6
mmol/L (100 mg/dL) and 6.05 mmol/L
(109mg/dL)areatincreasedrisk fordevel-
oping type 2 diabetes (39,40).More-recent
evidenceindicatesthatFPGconcentrations
even lower than 5.6 mmol/L (100 mg/dL)
are associated with a graded risk for type 2
diabetes (41). Data were obtained from
13,163 men between 26 and 45 years of
age who had FPG values ,5.55 mmol/L
(100 mg/dL) and were followed for a
mean of 5.7 years. Men with FPG values
of 4.83–5.05 mmol/L (87–91 mg/dL)
have a signiﬁcantly increased risk of type
2 diabetes, compared with men with FPG
values,4.5mmol/L(81mg/dL).Although
the prevalence of diabetes is low at these
glucose concentrations, the data support
the concept of a continuum between FPG
and the risk of diabetes.
B. Monitoring/prognosis. There is a di-
rect relationship between the degree of
chronic plasma glucose control and the
risk of late renal, retinal, and neurologic
complications. This correlation has been
documented in epidemiologic studies
and clinical trials for both type 1 (42)
and type 2 (43) diabetes. The important
causal role of hyperglycemia in the devel-
opmentandprogressionofcomplications
has been documented in clinical trials.
Persons with type 1 diabeteswho maintain
lower meanplasma glucose concentrations
exhibit a signiﬁcantly lower incidence of
microvascular complications—namely,
diabetic retinopathy, nephropathy, and
neuropathy(44).Althoughintensiveinsu-
lin therapy reduced hypercholesterolemia
by 34%, the risk of macrovascular disease
was not signiﬁcantly decreased in the
original analysis (44). Longer follow-up
documentedasigniﬁcantreductionincar-
diovascular disease in patients with type 1
diabetes treated with intensive glycemic
control (45). The effects of tight glycemic
controlonmicrovascularcomplicationsin
patients with type 2 diabetes (46) are sim-
ilartothosewithtype1diabetes,giventhe
differences in glycemia achieved between
theactive-interventionandcontrolgroups
in the various trials. Intensive plasma glu-
cose control signiﬁcantly reduced micro-
vascular complications in patients with
type 2 diabetes. Although meta-analyses
have suggested that intensive glycemic
control reduces cardiovascular disease in
individuals with type 2 diabetes (47,48),
clinical trials have not consistently dem-
onstrated a reduction in macrovascular
disease (myocardial infarction or stroke)
with intensive therapy aimed at lowering
glucose concentrations in type 2 diabetes.
Long-term follow-up of the United King-
dom ProspectiveDiabetes Study (UKPDS)
population supported a beneﬁt of inten-
sive therapy on macrovascular disease
(49), but three other recent trials failed
to demonstrate a signiﬁcant difference in
macrovascular disease outcomes between
very intensive treatment strategies, which
achievedHbA1cconcentrationsofapprox-
imately 6.5% (48 mmol/mol), and the
control groups,which had HbA1cconcen-
trations 0.8%–1.1% higher (50–52). One
studyevenobservedhighercardiovascular
mortality in the intensive-treatment arm
(50). In both the Diabetes Control and
Complications Trial (DCCT) and the
UKPDS,patientsintheintensive-treatment
group maintained lower median plasma
glucose concentrations; however, analyses
of the outcomes were linked to HbA1c,
Table 5—WHO criteria for interpreting 2-h OGTT
a
2-h OGTT result, mmol/L (mg/dL)
0h 2h
Impaired fasting glucose
b .6.1 (110) to ,7.0 (126) ,7.8 (140)
Impaired glucose tolerance
c ,7.0 (126) .7.8 (140) to ,11.1 (200)
Diabetes
d .7.0 (126) .11.1 (200)
aValues are for venous plasma glucose using a 75-g oral glucose load. From the WHO (19).
bIf 2-h glucose is
not measured, status is uncertain as diabetes or impaired glucose tolerance cannot be excluded.
cBoth fasting
and 2-h values need to meet criteria.
dEither fasting or 2-h measurement can be used. Any single positive
result should be repeated on a separate day.
RECOMMENDATION: ROUTINE
MEASUREMENT OF PLASMA GLUCOSE
CONCENTRATIONS IN AN ACCREDITED
LABORATORY IS NOT RECOMMENDED AS
THE PRIMARY MEANS OF MONITORING OR
EVALUATING THERAPY IN INDIVIDUALS
WITH DIABETES
B( l o w ) .
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Position Statementwhich was used to evaluate glycemic
control, rather than glucose concentration.
Moreover, most clinicians use the recom-
mendations of the ADA and other organi-
zations, which deﬁne a target HbA1c
concentration as the goal for optimum gly-
cemic control (21,53).
Neither random nor fasting glucose
concentrations should be measured in
an accredited laboratory as the primary
means of routine outpatient monitoring
of patients with diabetes. Laboratory
plasmaglucosetestingcanbeusedtosup-
plement information from other testing,
totesttheaccuracyofself-monitoring(see
below), or to adjust the dosage of oral
hypoglycemic agents (22,54). In addi-
tion, individuals with well-controlled
type 2 diabetes who are not on insulin
therapy can be monitored with periodic
measurement of the FPG concentration,
although analysis need not be done in
an accredited laboratory (54,55).
2. Rationale
A. Diagnosis. The disordered carbohy-
drate metabolism that underlies diabetes
manifests as hyperglycemia. Therefore,
measurement of either plasma glucose
or HbA1c is the diagnostic criterion. This
strategy is indirect, because hypergly-
cemia reﬂects the consequence of the
metabolic derangement, not the cause;
however, until the underlying molecular
pathophysiology of the disease is identi-
ﬁed, measurement of glycemia is likely to
remain an essential diagnostic modality.
B. Screening. Screeningisrecommended
for several reasons. The onset of type 2
diabetes is estimated to occur approxi-
mately 4–7 years (or more) before clinical
diagnosis (56), and epidemiologic evi-
dence indicates that complications may
begin several years before clinical diagno-
sis. Furthermore, it is estimated that 40%
of people in the U.S. with type 2 diabetes
are undiagnosed (8). Notwithstanding
this recommendation, there is no pub-
lished evidence that population screening
for hyperglycemia provides any long-
term beneﬁt. Outcome studies examining
thepotentiallong-termbeneﬁtsofscreen-
ing are ongoing.
3. Analytical considerations
A. Preanalytical. Blood should be drawn
in the morning after an overnight fast (no
caloric intake for at least 8 h), during
which time the individual may consume
water ad libitum (1). Published evidence
reveals diurnal variation in FPG, with the
mean FPG being higher in the morning
than in the afternoon, indicating that
many diabetes cases would be missed in
patients seen in the afternoon (57).
Loss of glucose from sample contain-
ers is a serious and underappreciated
problem (58). Decreases in glucose con-
centrationsinwholebloodexvivoaredue
to glycolysis. The rate of glycolysis—
reported to average 5%–7%/h [ap-
proximately 0.6 mmol/L (10 mg/dL)]
(59)—varies with the glucose concentra-
tion, temperature, leukocyte count, and
other factors (60). Such decreases in glu-
cose concentration will lead to missed di-
abetes diagnoses in the large proportion
of the population who have glucose con-
centrations near the cut points for diag-
nosis of diabetes.
The commonly used glycolysis inhib-
itors are unable to prevent short-term
glycolysis. Glycolysis can be attenuated
by inhibiting enolase with sodium ﬂuo-
ride (2.5 mg/mL of blood) or, less com-
monly,lithiumiodoacetate(0.5mg/mLof
blood). These reagents can be used alone
or, more commonly, with such anti-
coagulants as potassium oxalate, EDTA,
citrate,orlithiumheparin.Unfortunately,
although ﬂuoride helps to maintain long-
term glucose stability, the rates of decline
in the glucose concentration in the ﬁrst
hour after sample collection are virtually
identical for tubes with and without
ﬂuoride, and glycolysis continues for up
to4hinsamplescontainingﬂuoride(59).
After 4 h, the concentration of glucose
inwholebloodinthepresenceofﬂuoride
remainsstablefor72hatroomtemperature
(59) (leukocytosis will increase glycolysis
e v e ni nt h ep r e s e n c eo fﬂuoride if the leu-
kocyte count is very high).
Few effective and practical methods
are available for prompt stabilization of
glucose in whole-blood samples. Loss of
glucose can be minimized in two classic
ways: 1) immediate separation of plasma
from blood cells after blood collection
[the glucose concentration is stable for
8 h at 25°C and 72 h at 4°C in separated,
nonhemolyzed, sterile serum without
ﬂuoride (61)]; and 2) placing the blood
tube in an ice–water slurry immediately
after blood collection and separating the
plasma from the cells within 30 min
(19,62). These methods are not always
practical and are not widely used.
A recent study showed that acidiﬁca-
tionofbloodwithcitratebufferinhibitsin
vitro glycolysis far more effectively than
ﬂuoride (62). The mean glucose concen-
tration in samples stored at 37°C de-
creased by only 0.3% at 2 h and 1.2% at
24 h when blood was drawn into tubes
containing citrate buffer, sodium ﬂuo-
ride, and EDTA. The use of these blood-
collection tubes, where they are available,
appears to offer a practical solution to the
glycolysis problem.
Glucose can be measured in whole
blood, serum, or plasma, but plasma is
recommended for diagnosis [note that
although both the ADA and WHO rec-
ommend venous plasma, the WHO also
accepts measurement of glucose in capil-
lary blood (19,21)]. The molality of glu-
cose (i.e., the amount of glucose per unit
water mass) in whole blood is identical
to that in plasma. Although erythrocytes
are essentially freely permeable to glu-
cose (glucose is taken up by facilitated
transport), the concentration of water (in
kilograms per liter) in plasma is approxi-
mately 11% higher than in whole blood.
Therefore, glucose concentrations are ap-
proximately11% higher inplasmathanin
whole blood if the hematocrit is normal.
Glucose concentrations in heparinized
plasma were reported in 1974 to be 5%
lower than in serum (63). The reasons for
the difference are not apparent but have
been attributed to the shift in ﬂuid from
erythrocytes to plasma caused by anti-
coagulants. In contrast, some more recent
studies found that glucose concentrations
are slightly higher in plasma than in se-
rum. The observed differences were ap-
proximately 0.2 mmol/L (3.6 mg/dL)
(64), or approximately 2% (65), or 0.9%
(62). Other studies have found that glu-
cose values measured in serum and
RECOMMENDATION: BLOOD FOR FPG
ANALYSIS SHOULD BE DRAWN IN THE
MORNING AFTER THE INDIVIDUAL HAS
FASTED OVERNIGHT (AT LEAST 8h )
B( l o w ) .
RECOMMENDATION: TO MINIMIZE
GLYCOLYSIS, ONE SHOULD PLACE THE
SAMPLE TUBE IMMEDIATELY IN AN
ICE–WATER SLURRY, AND THE PLASMA
SHOULD BE SEPARATED FROM THE CELLS
WITHIN 30 MIN. IF THAT CANNOT BE
ACHIEVED, A TUBE CONTAINING A
RAPIDLY EFFECTIVE GLYCOLYSIS
INHIBITOR, SUCH AS CITRATE BUFFER,
SHOULD BE USED FOR COLLECTING THE
SAMPLE. TUBES WITH ONLY ENOLASE
INHIBITORS, SUCH AS SODIUM FLUORIDE,
SHOULD NOT BE RELIED ON TO PREVENT
GLYCOLYSIS
B (moderate).
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Sacks and Associatesplasma are essentially the same (66,67).
Giventheseﬁndings,itisunlikelythatval-
ues for plasma and serum glucose will be
substantially different when glucose is as-
sayed with current instruments, and any
differences will be small compared with
the day-to-day biological variation of glu-
cose. Clinicalorganizations donot recom-
mend the measurement of glucose in
serum (rather than plasma) for the diag-
nosis of diabetes (19,21). Use of plasma
allowssamplestobecentrifugedpromptly
to prevent glycolysis without waiting for
the blood to clot. The glucose concentra-
tionsincapillarybloodobtainedduringan
OGTT are signiﬁcantly higher than those
in venous blood [mean, 1.7 mmol/L (30
mg/dL), which is equivalent to 20%–25%
higher (68)], probably owing to glucose
consumption in the tissues. In contrast,
the mean difference in fasting samples is
only 0.1 mmol/L (2 mg/dL) (68,69).
Reference intervals. Glucose concentrations
vary with age in healthy individuals. The
reference interval for children is 3.3–5.6
mmol/L (60–100 mg/dL), which is similar
to the adult interval of 4.1–6.1 mmol/L
(74–110 mg/dL) (70). Note that the ADA
and WHO criteria (19,21), not the refer-
ence intervals, are used for the diagnosis
of diabetes. Moreover, the threshold for
the diagnosis of hypoglycemia is variable.
Reference intervals are not useful for diag-
nosing these conditions. In adults, the
mean FPG concentration increases with
increasing age from the third to the sixth
decade (71) but does not increase signiﬁ-
cantlyafter60yearsofage(72,73).Bycon-
trast,glucoseconcentrationsafteraglucose
challenge are substantially higher in older
individuals (72,73). The evidence for an
association between increasing insulin re-
sistance and age is inconsistent (74). Aging
appears to inﬂuence glucose homeostasis,
andvisceralobesityseemstoberesponsible
for the reported continuous decrease in
glucose tolerance that begins in middle
age (75).
B. Analytical. Glucose is measured al-
most exclusively by enzymatic methods.
An analysis of proﬁciency surveys con-
ducted by the College of American Pa-
thologists (CAP) reveals that hexokinase
or glucose oxidase is used in virtually all
analyses performed in the U.S. (70). A
very few laboratories (,1%) use glucose
dehydrogenase. Enzymatic methods for
glucose analysis are relatively well stan-
dardized. At a plasma glucose concentra-
tion of approximately 7.5 mmol/L (135
mg/dL), the imprecision (CV) among lab-
oratories that used the same method was
#2.6% (70). Similar ﬁndings have been
reported for glucose analyses of samples
from patients. The method of glucose
measurement does not inﬂuence the re-
sult. A comparison of results from ap-
proximately 6,000 clinical laboratories
reveals that the mean glucose concentra-
tions measured in serum samples by the
hexokinase and glucose oxidase methods
are essentially the same (76). Compared
with a reference measurement procedure,
signiﬁcant bias (P , 0.001) was observed
for 40.6% of the peer groups (76). If sim-
ilar biases occur with plasma, patients
near the diagnostic threshold could be
misclassiﬁed.
No consensus has been achieved on
the goals for glucose analysis. Numerous
criteria have been proposed to establish
analytical goals. These criteria include
expert opinion (consensus conferences),
the opinion of clinicians, regulation, the
state of the art, and biological variation
(77). A rational and realistic recommen-
dation that has received some support
is to use biological criteria as the basis
for analytical goals. It has been suggested
that imprecision should not exceed one-
half of the within-individual biological
CV (78,79). For plasma glucose, a CV
#2.2% has been suggested as a target
for imprecision, with a 0% bias (79). Al-
though this recommendation was pro-
posed for within-laboratory error, it
would be desirable to achieve this goal
for interlaboratory imprecision to mini-
mize differences among laboratories in
the diagnosis of diabetes in individuals
with glucose concentrations close to the
threshold value. Therefore, the goal for
glucose analysis should be to minimize
totalanalyticalerror,andmethodsshould
be without measurable bias. A national or
international program that uses commut-
able samples (e.g., fresh frozen plasma) to
eliminate matrix effects and has accuracy-
based grading with values derived with a
referencemeasurementprocedureshould
be developed to assist in achieving this
objective.
4. Interpretation
Despite the low analytical imprecision at
the diagnostic decision limits of 7.0
mmol/L (126 mg/dL) and 11.1 mmol/L
(200 mg/dL), classiﬁcation errors may
occur. Knowledge of intraindividual
(within-person) variation in FPG concen-
trations is essential for meaningful inter-
pretation of patient values (although total
biological variationincludes within-person
and between-person variation, most dis-
cussions focus on the within-person var-
iation).Anearlystudy,whichrepeatedthe
OGTT in 31 nondiabetic adults at a 48-h
interval, revealed that the FPG concentra-
tionvariedbetweenthe2valuesby,10%
in 22 participants (77%) and by ,20% in
30 participants (97%) (80). A careful eval-
uation of healthy individuals over several
consecutive days revealed that the biolog-
ical variation in FPG [mean glucose, 4.9
mmol/L (88 mg/dL)] exhibited within-
and between-individual CVs of 4.8%–
6.1% and 7.5%–7.8%, respectively
(81–83). Larger studies have revealed
intraindividual CVs of 4.8% and 7.1%
for FPG in 246 healthy individuals and
80 previously undiagnosed individuals
with diabetes, respectively (83). Similar
ﬁndings were obtained from an analysis
of 685 adults from NHANES III, in which
the mean within-person variation in FPG
measured 2–4 weeks apart was 5.7%
(95% CI, 5.3%–6.1%) (84). An analysis
of larger numbers of individuals from
t h es a m eN H A N E SI I Id a t a b a s ey i e l d e d
within- and between-person CVs of
8.3%and12.5%,respectively,ataglucose
concentration of approximately 5.1
mmol/L (92 mg/dL) (85). If a within-
person biological CV of 5.7% is applied
to a true glucose concentration of 7.0
mmol/L (126 mg/dL), the 95% CI would
encompassglucoseconcentrationsof6.2–
7.8 mmol/L (112–140 mg/dL). If the
analytical CV of the glucose assay (ap-
proximately 3%) is included, the 95% CI
is approximately 612.88%. Thus, the
95%CIforafastingglucoseconcentration
of 7.0 mmol/L (126 mg/dL) would be 7.0
mmol/L 6 6.4% (126 mg/dL 6 6.4%),
i.e., 6.1–7.9 mmol/L (110–142 mg/dL).
Use of an assay CV of 3% only (excluding
biologicalvariation)wouldyield a95% CI
of 6.6–7.4 mmol/L (118–134 mg/dL)
amonglaboratories,foratrueglucosecon-
centration of 7.0 mmol/L (126 mg/dL).
Performing the same calculations at the
cutoff for impaired fasting glucose yields a
RECOMMENDATION: ON THE BASIS OF
BIOLOGICAL VARIATION, GLUCOSE
MEASUREMENT SHOULD HAVE AN
ANALYTICAL IMPRECISION £2.9%, AB I A S
£2.2%, AND A TOTAL ERROR £6.9%. TO
AVOID MISCLASSIFICATION OF PATIENTS,
THE GOAL FOR GLUCOSE ANALYSIS
SHOULD BE TO MINIMIZE TOTAL
ANALYTICAL ERROR, AND METHODS
SHOULD BE WITHOUT MEASURABLE BIAS
B( l o w ) .
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Position Statement95% CI of 5.6 mmol/L 6 6.4% (100
mg/dL 6 6.4%), i.e., 4.9–6.3 mmol/L
(87–113 mg/dL). One should bear in
mind that these intervals include 95% of
the results and that the remaining 5% will
beoutsidethisinterval.Thus,thebiological
variation is substantially greater than the
analytical variation. Using biological varia-
tion as the basis for deriving analytical per-
formance characteristics (77), Westgard
proposed the following desirable speciﬁ-
cationsforglucose(86):analyticalimpre-
cision, #2.9%; bias, #2.2%; and total
error, #6.9%.
A. Turnaround time. Ashortturnaround
time for glucose analysis is not usually
necessaryfordiagnosisofdiabetes.Insome
clinical situations, such as acute hyper- or
hypoglycemic episodes in the emergency
department or treatment of diabetic keto-
acidosis (DKA), rapid analysis is desirable.
A turnaround time of 30 min has been
proposed (87). This value is based on the
suggestions of clinicians, however, and no
outcomedatathatvalidatethistimeinterval
have been published. Inpatient manage-
ment of diabetic patients on occasion may
require a rapid turnaround time (minutes,
not hours). Similarly, for protocols with in-
tensive glucose control in critically ill pa-
tients (88), rapid glucose results are
required in order to calculate the insulin
dose. Bedside monitoring with glucose me-
ters (see below) has been adopted by many
as a practical solution.
B. Frequency of measurement. The fre-
quency of measurement of plasma glucose
is dictated by the clinical situation. The
ADA, WHO, and IDF recommend that an
increasedFPGoranabnormalOGTTresult
must be conﬁrmed to establish the diag-
nosisofdiabetes(19,89).ScreeningbyFPG
is recommended every 3 years, beginning
at 45 years of age and more frequently in
high-risk individuals; however, the fre-
quency of analysis has not been speciﬁed
for the latter group. Monitoring is per-
formed by patients who measure their glu-
cose themselves with meters and by
assessment of HbA1c in an accredited labo-
ratory(seebelow).Theappropriateinterval
between glucose measurements in acute
clinical situations (e.g., patients admitted
to a hospital, patients with DKA, neonatal
hypoglycemia, and so forth) is highly vari-
ableand mayrangefrom30minto24hor
more.
5. Emerging considerations
Continuous minimally invasive and non-
invasive analysis of glucose is addressed
below.
GLUCOSE METERS—Portable me-
ters for the measurement of blood glucose
concentrations are used in three major
settings: 1)i na c u t e -a n dc h r o n i c - c a r ef a c i l -
ities, including intensive care units (ICUs);
2) in physicians’ ofﬁces; and 3) by patients
at home, work, and school. Measurement
in the last setting, self-monitoring of blood
glucose (SMBG), was performed at least
once per day by 40% and 26% of individ-
uals with type 1 and type 2 diabetes, re-
spectively, in the U.S. in 1993 (90). The
overall rate of daily SMBG among adults
with diabetes in the U.S. increased to
40.6% in 1997 and to 63.4% in 2006
(91). The ADA summarized the uses of
SMBG as early as 1987 [see (92) and refer-
ences therein] and currently recommends
thatSMBGbecarriedout$3timesdailyby
patients who use multiple insulin injec-
tions or insulin pump therapy (92,93). It
isrecommendedthatmostindividualswith
diabetes attempt to achieve and maintain
blood glucose concentrations as close to
thoseinnondiabeticindividualsasissafely
possible.
1. Use
A. Diagnosis/screening. The glucose-
based criteria for the diagnosis of di-
abetes are based on outcome data (the
risk of micro- and macrovascular dis-
ease) correlated with plasma glucose
concentrations—both fasting and 2 h
after a glucose load—a s s a y e di na na c -
credited laboratory (1). Whole blood is
used in portable meters. Although most
portable meters have been programmed
to report a plasma glucose concentration,
the imprecision of the current meters (see
below) precludes their use from the di-
agnosis of diabetes. Similarly, screening
with portable meters—although attrac-
tive because of convenience, ease, and
accessibility—would generate many
false positives and false negatives.
B. Monitoring/prognosis. SMBG is rec-
ommendedfor allinsulin-treated patients
with diabetes. Intensive glycemic control
can decrease microvascular complica-
tions in individuals with type 1 (44) or
type 2 (46) diabetes. In the DCCT, pa-
tientswithtype1diabetesachievedinten-
sive glycemic control by performing
SMBG at least 4 times per day (44). Ther-
apy in patients with type 2 diabetes in the
UKPDS (46) was adjusted according to
FPG concentration; SMBG was not evalu-
ated.
The role of SMBG in individuals with
type 2 diabetes has generated consider-
able controversy (94,95). Faas et al. (96)
reviewed 11 studies published between
1976 and 1996 that evaluated SMBG in
patients with type 2 diabetes. Only one of
thepublishedstudiesreportedthatSMBG
produced a signiﬁcant improvement in
glycated Hb (GHb). The review’sa u t h o r s
concluded that the efﬁcacy of SMBG in
type 2 diabetes is questionable (96). Sim-
ilar conclusions were drawn in an early
(2000) meta-analysis (97) of a sample
of patients with type 2 diabetes in
theNHANES(98)and theFreemantleDi-
abetes Study (99). Two early randomized
trials assessed the use of glucose meters
in individuals with type 2 diabetes
RECOMMENDATION: THERE ARE
INSUFFICIENT PUBLISHED DATA
OUTCOME TO SUPPORT A ROLE FOR
PORTABLE METERS AND SKIN-PRICK
(FINGER-STICK) BLOOD SAMPLES IN THE
DIAGNOSIS OF DIABETES OR FOR
POPULATION SCREENING
C (moderate).
RECOMMENDATION: THE IMPRECISION OF
THE RESULTS, COUPLED WITH THE
SUBSTANTIAL DIFFERENCES AMONG
METERS, PRECLUDES THE USE OF
GLUCOSE METERS FROM THE DIAGNOSIS
OF DIABETES AND LIMITS THEIR
USEFULNESS IN SCREENING FOR DIABETES
A( m o d e r a t e ) .
RECOMMENDATION: SMBG
IS RECOMMENDED FOR ALL
INSULIN-TREATED PATIENTS
WITH DIABETES
A( h i g h ) .
RECOMMENDATION: IN PATIENTS WITH
TYPE 2 DIABETES TREATED WITH DIET
AND ORAL AGENTS, SMBG MAY HELP
ACHIEVE BETTER CONTROL,
PARTICULARLY WHEN THERAPY IS
INITIATED OR CHANGED. DATA ARE
INSUFFICIENT, HOWEVER, TO CLAIM AN
ASSOCIATED IMPROVEMENT OF HEALTH
OUTCOMES. THE ROLE OF SMBG IN
PATIENTS WITH STABLE TYPE 2 DIABETES
CONTROLLED BY DIET ALONE IS
NOT KNOWN
C( h i g h ) .
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Sacks and Associates(100,101). One of these trials (100) had
statistical power to detect a 0.5% reduc-
tion in HbA1c but reported only a modest
decrease (0.3%) in HbA1c among poorly
controlled patients treated with oral
agents. The second study (101) failed to
demonstrate a signiﬁcant difference in
HbA1c in patients who were assigned to
use meters, compared with those who
were not.
For individuals with type 2 diabetes,
cross-sectional and longitudinal obser-
vational studies in several countries have
failedto demonstrateanimprovementin
glycemic control (as measured by mean
HbA1c concentration) associated with
the use of SMBG (102–104). This lack
of effect was seen in individuals treated
with insulin, oral agents, or both. Fre-
quency of meter use did not predict
HbA1c.
A 2005 Cochrane review (105,106)
of self-monitoring in individuals with
type 2 diabetes not using insulin con-
cluded that SMBG might be effective in
improving glucose control. There was in-
sufﬁcient evidence to evaluate whether it
wasbeneﬁcialinimprovingqualityoflife,
improving well-being or patient satisfac-
tion, or decreasing the number of hypo-
glycemic episodes.
The randomized controlled Diabetes
Glycaemic Education and Monitoring
(DiGEM) trial (107) studied people with
type 2 diabetes, a third of whom were
treated with diet alone. In 2007, the in-
vestigators reported, “Evidence is not
convincing of an effect of self monitoring
blood glucose ...in improving glycaemic
control [as assessed by HbA1c]c o m p a r e d
with usual care in reasonably well con-
trolled non-insulin treated patients with
type 2 diabetes.” A cost-effectiveness
analysis of data from the DiGEM trial
concluded,“Selfmonitoringofbloodglu-
cose with or without additional training
in incorporating the results into self care
was associated with higher costs and
lower quality of life in patients with
non-insulin treated type 2 diabetes. In
light of this, and no clinically signiﬁcant
differences in other outcomes, self mon-
itoring of blood glucose is unlikely to be
cost effective in addition to standardised
usual care” (108).
ThelaterESMONstudy(109),aran-
domized controlled trial of SMBG in
newly diagnosed people with diabetes
nottreatedwithinsulin,foundnobeneﬁt
of SMBG on glycemic control but did
ﬁnd higher scores on a depression sub-
scale.
Two recent systematic reviews of
randomized controlled studies of SMBG
in people with type 2 diabetes not treated
with insulin reported small but signiﬁ-
cantly greater decreases in HbA1c among
patients using SMBG than in controls
(110,111). In the ﬁrst review (110),
SMBG was associated with a larger reduc-
tion in HbA1c compared with non-SMBG
(weighted mean difference, 20.31%;
95% CI, 20.44 to 20.17). In the second
study (111), the relative decrease in
HbA1c was 20.24% (95% CI, 20.34%
to 20.14%). The effect of SMBG was
limited to patients with HbA1c values
$8% (64 mmol/mol).
A 2009 review of studies of patients
with type 2 diabetes (112) addressed re-
cent large randomized trials of tight gly-
cemiccontrol,amajorrationaleforSMBG
use in these patients. It concluded that
“tight glycemic control burdens patients
with complex treatment programs, hypo-
glycemia, weight gain, and costs and of-
fers uncertain beneﬁts in return,” thus
raising additional uncertainty about
the use of SMBG in people with type 2
diabetes.
2. Rationale
Knowledge of ambient plasma or blood
glucose concentrationsisused by insulin-
requiring patients, particularly those with
type 1 diabetes, as an aid in determining
appropriate insulin doses at different
times of the day (92). Patients adjust the
amount of insulin according to their
plasma or blood glucose concentration.
Frequent SMBG is particularly impor-
tant for tight glycemic control in type 1
diabetes.
Hypoglycemiaisamajor,potentially
life-threatening complication of the
treatment of diabetes. The risk of hy-
poglycemia is seen primarily in patients
treated with insulin or insulin secre-
tagogues, and it increases substantially
when pharmacologic therapy is directed
towards maintaining the glycemic con-
centrations as close to those found in
nondiabetic individuals as is safely possi-
ble (44,46). The incidence of major hypo-
glycemic episodes—requiring third-party
help or medical intervention—was 2- to
3-fold higher in the intensive-treatment
group than in the conventional group
in clinical trials of patients with type 1
and type 2 diabetes (44,46). Fur-
thermore, many patients with diabetes,
particularly those with type 1, lose
the autonomic warning symptoms that
normally precede neuroglycopenia
(“hypoglycemic unawareness”) (113),
increasing the risk of hypoglycemia.
SMBGcanbeusefulfordetectingasymp-
tomatic hypoglycemia and allowing pa-
tients to avoid major hypoglycemic
episodes.
3. Analytical considerations
A. Preanalytical. Numerous factors
can interfere with glucose analysis with
portable meters. Several of these factors,
such as improper application, timing,
and removal of excess blood (61), have
been mitigated or eliminated by advan-
ces in technology. Important variables
that may inﬂuence the results of bedside
glucose monitoring include changes in
hematocrit (114), altitude, environmen-
tal temperature or humidity, hypoten-
sion, hypoxia and high triglyceride
concentrations (115), and various
drugs. Furthermore, most meters are in-
accurate atveryhighorvery lowglucose
concentrations. Another important fac-
torisvariationinresultsamongdifferent
glucose meters. Different assay methods
and architectures lead to a lack of corre-
lation among meters, even from a single
manufacturer. In fact, two meters of the
same brand have been observed to differ
substantially in accuracy (116,117).
Patientfactorsarealsoimportant,partic-
ularly adequate training. Recurrent edu-
cation at clinic visits and comparison of
SMBG with concurrent laboratory glu-
cose analysis improved the accuracy
of patients’ blood glucose readings
(118). Thus, it is important to evaluate
the patient’s technique at regular inter-
vals (21). In addition to these technical
issues, the anatomic site where skin-
puncture samples are obtained inﬂu-
encesresults.Testingbloodfromso-called
alternative sites may introduce a tempo-
ral lag in changes in measured blood
glucose.
RECOMMENDATION: PATIENTS SHOULD
BE INSTRUCTED IN THE CORRECT USE OF
GLUCOSE METERS, INCLUDING QUALITY
CONTROL. COMPARISON BETWEEN SMBG
AND CONCURRENT LABORATORY
GLUCOSE ANALYSIS SHOULD BE
PERFORMED AT REGULAR INTERVALS TO
EVALUATE THE PERFORMANCE OF THE
METERS IN THE PATIENT’SH A N D S
B (moderate).
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Position StatementB. Analytical. Virtuallyallglucosemeters
use strips that contain enzymes, such as
glucose oxidase or glucose dehydroge-
nase.Adropofwholebloodisappliedtoa
strip that contains all the reagents neces-
sary for the assay. Some meters have a
porous membrane that separates erythro-
cytes, and analysis is performed on the
resultantplasma.Meterscanbecalibrated
to report plasma glucose values, even
when the sample is whole blood. An
IFCC working group recommended that
glucose meters report the plasma glucose
concentration, irrespective of the sample
type or technology (119,120). This ap-
proach can improve harmonization
and allow comparison with laboratory-
generated results (121). The meters use
reﬂectance photometry or electrochemis-
try to measure the rate of the reaction or
the ﬁnal concentration of the products,
and they provide digital readouts of glu-
cose concentration. Manufacturers claim
reportable concentration ranges as large as
33.3 mmol/L (600 mg/dL), e.g., 0–33.3
mmol/L (0–600 mg/dL).
Several important technological ad-
vances decrease operator error. These
improvements include automatic com-
mencement of timing when both the
sample and the strip are in the meter,
smaller sample-volume requirements, an
error signal if the sample volume is in-
adequate, “lock out” if controls are not
assayed, and bar code readers to identify
the lot of the strips. Moreover, meters
store up to several hundred results that
can subsequently be downloaded for
analysis. Together, these improvements
have improved the performance of new
meters (122,123). Nonetheless, meter
performance in the hands of patients
does not equal potential performance as
judged by performance in the hands of
skilled medical technologists (124).
Numerous analytical goals have been
proposed for the performance of glucose
meters. The rationale for these goals is not
alwaysclear.In1987,theADArecommen-
ded a goal of total error (user plus analyt-
ical) of ,10% at glucose concentrations of
1.7–22.2 mmol/L (30–400 mg/dL) 100%
of the time (125). In addition, the ADA
proposed that values should differ by
#15%fromthoseobtainedbyalaboratory
reference method. The recommendation
was modiﬁed in response to the signiﬁcant
reduction in complications obtained by
tight glucose control in the DCCT. A re-
vised performance goal, published in
1996 (92), was for a total analytical error
of ,5%. To our knowledge, there are no
published studies of diabetic patients
achieving the goal of an analytical error of
,5% with any glucose meters.
The less stringent CLSI (formerly
NCCLS) recommendations are that, for
95% of the samples, the difference be-
tween meter and laboratory measure-
ments of glucose be 1) ,20% when the
laboratory glucose value is .5.5 mmol/L
(100 mg/dL) and 2) ,0.83 mmol/L (15
mg/dL) of the laboratory glucose value
when the glucose concentration is #5.5
mmol/L (100 mg/dL) (126). The 2003
International Organization for Standard-
ization (ISO) recommendations (127)
propose that for test readings .4.2
mmol/L (75 mg/dL), the discrepancy be-
tween meters and an accredited labora-
tory should be ,20%; for glucose
readings #4.2 mmol/L (75 mg/dL), the
discrepancy should not exceed 0.83
mmol/L (15 mg/dL) in 95% of the sam-
ples.InboththeCLSIandISOguidelines,
5% of these results can be substantially
o u t s i d et h e s el i m i t s .A tt h et i m eo fw r i t -
ing,boththeCLSIandISOrecommenda-
tions were undergoing revision.
These criteria serve as de facto min-
imal quality requirements for manufac-
turers wishing to sell meters. With these
criteria, a concentration of 2.5 mmol/L
(45 mg/dL) may be read as 1.7 mmol/L
(30 mg/dL) or 3.3 mmol/L (60 mg/dL)
andbeconsideredacceptable.Sucherrors
do notappear tobeacceptableforreliably
detecting hypoglycemia. Similarly, errors
of 20% can lead to errors in insulin
dosing, which, when combined with
other factors, can lead to hypoglycemia.
Others have proposed different ap-
proaches to establishing quality require-
ments. Clarke et al. (128) developed an
errorgridthatattemptstodeﬁneclinically
important errors by identifying fairly
broad target ranges. In another approach,
201 patients with long-standing type 1
diabetes were questioned to estimate
quality expectations for glucose meters
(129). On the basis of patients’ percep-
tions of their needs and their reported
actions in response to changes in mea-
sured glucose concentrations, a goal for
analytical quality at hypoglycemic con-
centrations was a CV of 3.1%. With hy-
poglycemiaexcluded,theanalyticalCVto
meet the expectations of 75% of the pa-
tients was 6.4% to 9.7%. The authors rec-
ommended an analytical CV of 5% with a
bias #5% (129). A third approach used
simulation modeling of errors in insulin
dose(130).Theresultsrevealedthatmeters
that achieve both a CV and a bias ,5%
rarely lead to major errors in insulin dose.
To provide the intended insulin dosage
95% of the time, however, the bias and
CV needed to be ,1%–2%, depending
on the dosing schedule for insulin and
the intervals of glucose concentrations for
the individual patient (130). No meters
have been shown to achieve CVs of 1%–
2% in routine use in the hands of patients.
The lack of consensus on quality
goals for glucose meters reﬂects the ab-
sence of agreed objective criteria. With
the same biological-variation criteria de-
scribed above for glucose analysis in
accredited laboratories (section 4, Inter-
pretation), a biological goal would be a
totalerror#6.9%withanimprecision(as
theCVofmeasurementsoverseveraldays
or weeks) #2.9% and a bias #2.2% (86).
Additional studies, however, are neces-
sarytodeﬁneagoalthatisrelatedtomed-
ical needs.
Current meters exhibit performance
superior to prior generations of meters
(122,123). A variety of studies of newer
analyzers have documented CVs of about
2% in the hands of trained workers.
Nonetheless, there is room for improve-
ment. In a study conducted under care-
fully controlled conditions in which a
single medical technologist performed
alloftheassays,about50%oftheanalyses
RECOMMENDATION: METERS SHOULD
MEASURE AND REPORT PLASMA GLUCOSE
CONCENTRATIONS TO FACILITATE
COMPARISON WITH ASSAYS PERFORMED
IN ACCREDITED LABORATORIES
GPP.
RECOMMENDATION: MULTIPLE
PERFORMANCE GOALS FOR PORTABLE
GLUCOSE METERS HAVE BEEN PROPOSED.
THESE TARGETS VARY WIDELY AND ARE
HIGHLY CONTROVERSIAL.
MANUFACTURERS SHOULD WORK TO
IMPROVE THE IMPRECISION OF CURRENT
METERS, WITH AN INTERMEDIATE GOAL
OF LIMITING TOTAL ERROR FOR 95% OF
SAMPLES TO £15% AT GLUCOSE
CONCENTRATIONS ‡5.6 mmol/L
(100 mg/dL) AND TO ,0.8 mmol/L
(15 mg/dL) AT GLUCOSE
CONCENTRATIONS ,5.6 mmol/L
(100 mg/dL). LOWER TOTAL ERROR
WOULD BE DESIRABLE AND MAY PROVE
NECESSARY IN TIGHT GLUCOSE-CONTROL
PROTOCOLS AND FOR AVOIDING
HYPOGLYCEMIA IN ALL SETTINGS
C( l o w ) .
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Sacks and Associatesmet the 1996 ADA criterion of ,5% de-
viation from reference intervals (122).
Another study that evaluated meter per-
formance in 226 hospitals with split sam-
ples analyzed simultaneously on meters
and laboratory glucose analyzers revealed
that 45.6%, 25%, and 14% of the split
s a m p l e sd i f f e r e df r o me a c ho t h e rb y
.10%, .15%, and .20%, respectively
(131). In another study, none of the me-
ters met the 1996 ADA criterion (132). In
an evaluation in which “all testing was
performed by trained study staff in an in-
patient Clinical Research Center setting,”
only 81% of results with a meter that
used a hexokinase method were within
10% of results obtained from an accred-
ited laboratory (133). We are aware of no
studies that document patient-generated
results that meet the 1996 ADA criteria.
Moreover, an analysis of published stud-
ies of glucose meters demonstrated that
the studies suffered from deﬁciencies in
study design, methodology, and report-
ing (134), raising the possibility that the
reported total error underestimates the
true total error of the meters. A standard-
ized method for evaluating meters has
been developed in Norway (134), and
the Norwegian health authorities have
decided that all SMBG instruments mar-
ketedinNorwayshouldbeexaminedbya
similar procedure (135). Results of evalu-
ations of nine brands of meters according
to this method showed that three of nine
meters did not meet the ISO criteria, and
none met the 1996 ADA criteria in the
hands of patients (135).
Glucose meters are also used to sup-
port tight control of glucose in patients in
ICU settings. A 2001 report of a seminal
randomized controlled trial by van den
Bergheetal.describeda34%reductionin
mortality in surgical ICU patients man-
aged according to a tight glucose-control
protocol(88).Ameta-analysisofmultiple
randomized controlled trials of tight glu-
cosecontrolconducted7yearslaterfailed
to identify any improved outcomes but
did ﬁnd an increased incidence of hypo-
glycemia (136). A Clinical Chemistry Per-
spective article (137) pointed out that the
study of van den Berghe et al. used a pre-
cise and accurate glucose analyzer and
collected arterial blood samples, whereas
subsequent studies often used glucose
meters and capillary blood samples ob-
tained by ﬁnger stick. The integrity of re-
sults obtained with ﬁnger-stick samples
can be compromised by such factors as
shock, hypoxia, and low hematocrit,
which are common in these settings
(138). Moreover, the error of glucose me-
ters may compound the problem and
compromise the ability to control blood
glucose and avoid hypoglycemia. Simula-
tion modeling studies have demonstrated
that errors in glucose measurement
(which include errors related to sample
type and sample collection) lead to
marked degradation of glycemic control
in tight glucose-control protocols (139).
In this study, frequencies of both hy-
perglycemia and hypoglycemia were
increased with increasing assay impreci-
sion. In a 2005 study of ICU patients
(140), the agreement of meter results
with accredited laboratory results was
p o o r :A m o n g7 6 7p a i r e dr e s u l t s ,t h e
95% limits of agreement were 12.4 to
21.5 mmol/L (143.1 to 227.2 mg/dL).
Hoedemaekers et al. (141), in a study of
197 arterial blood samples from ICU pa-
tients, reported that the evaluated meter
did not meet the ISO total-error criteria.
They also demonstrated that the total
error of meters used in ICU patients was
greater than in non-ICU patients. A later
report, which also studied arterial blood
from ICU patients, measured glucose in
239 samples by a portable meter and by a
laboratory method and found that the
meter results did not meet the CLSI/ISO
criteria (142). Similarly, a 2005 study of
arterial, venous, and capillary samples
fromamixedmedical/surgicalICUofater-
tiary care hospital in Canada found that
meters did not meet proposed CLSI goals
but that a blood gas analyzer did (143).
4. Interpretation
A. Frequency of measurement. SMBG
should be performed at least 3 times per
day in patients with type 1 diabetes.
Monitoring less frequently than 3 times
per day leads to deterioration in glycemic
control (92,144,145). Patients perform
self-monitoring much less frequently
than recommended. Data from NHANES
III collected between 1988 and 1994 re-
veal that SMBG was performed at least
once a day by 39% of patients taking in-
sulin and by 5%–6% of patients treated
with oral agents or diet alone (98). More-
over, 29% and 65% of patients treated
with insulin and oral agents, respectively,
monitored their blood glucose less than
once per month; however, no evaluation
has been performed to verify that 3 times
per day is ideal or whether a different fre-
quency would improve glycemic control.
For example, adjustment of insulin ther-
apyinwomenwithGDMaccordingtothe
results of postprandial, rather than pre-
prandial, plasma glucose concentrations
improved glycemic control and reduced
the risk of neonatal complications (146).
The optimal frequency of SMBG for pa-
tients with type 2 diabetes is unknown.
The ADA recommends that patients
treated with multiple daily injections of
insulin perform SMBG $3t i m e sp e rd a y
(21) and states that “SMBG is useful in
achieving glycemic goals” in other pa-
tients. The last statement is based on ex-
pert opinion.
CONTINUOUS MINIMALLY
INVASIVE GLUCOSE
ANALYSES
1. Use
RECOMMENDATION: STUDIES ARE
NEEDED TO DETERMINE THE ANALYTICAL
GOALS (QUALITY SPECIFICATIONS) FOR
GLUCOSE METERS IN SMBG AND IN ICUS
C (moderate).
RECOMMENDATIONS FOR FUTURE
RESEARCH: IMPORTANT END POINTS IN
STUDIES OF SMBG SHOULD INCLUDE, AT A
MINIMUM, HbA1c AND FREQUENCY OF
HYPOGLYCEMIC EPISODES TO ASCERTAIN
WHETHER IMPROVED METERS ENABLE
PATIENTS TO ACHIEVE BETTER GLUCOSE
CONTROL. FOR STUDIES OF METER USE IN
INTENSIVE OR CRITICAL CARE,
IMPORTANT END POINTS INCLUDE MEAN
BLOOD GLUCOSE, FREQUENCY OF
HYPOGLYCEMIA, AND VARIATION OF
GLUCOSE CONTROL. IDEALLY, OUTCOMES
(e.g., LONG-TERM COMPLICATIONS)
SHOULD ALSO BE EXAMINED
GPP.
RECOMMENDATION: REAL-TIME
CONTINUOUS GLUCOSE MONITORING
(CGM) IN CONJUNCTION WITH INTENSIVE
INSULIN REGIMENS CAN BE A USEFUL
TOOL TO LOWER HbA1c IN SELECTED
ADULTS (AGE >25 YEARS) WITH TYPE 1
DIABETES
A( h i g h ) .
RECOMMENDATION: ALTHOUGH THE
EVIDENCE FOR LOWERING HbA1c IS NOT
AS STRONG FOR CHILDREN, TEENS, AND
YOUNGER ADULTS, REAL-TIME CGM MAY
BE HELPFUL IN THESE GROUPS. SUCCESS
CORRELATES WITH ADHERENCE TO
ONGOING USE OF THE DEVICE
B (moderate).
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Position StatementThe development of a device for “contin-
uous” in vivo monitoring of glucose con-
centrations in blood has become a very
high priority as patients are required to
control their plasma glucose more closely
(21,44,147).Theﬁrst device approved by
the U.S. Food and Drug Administration
(FDA) for minimally invasive interstitial
ﬂuid glucose sensing, the transcutaneous
GlucoWatch Biographer, is no longer on
the market. Several implanted-catheter
systems have subsequently been ap-
proved. The initial device in the latter
category is the Continuous Glucose Mon-
itoring System (CGMS) (Medtronic), a
system that does not provide real-time
data to the patient, but rather one the pa-
tient wears for 3 days and then returns to
the provider’so f ﬁce for its data to be
downloaded for trend analyses. More
recently, a number of real-time devices
that allow patients to read both current
glucose concentrations and trends have
become commercially available. In the
U.S., these devices include the Guardian
Real-Time (Medtronic Diabetes), the
Seven Plus System (DexCom), and the
Freestyle Navigator (Abbott Laborato-
ries). CGM devices require calibration
and conﬁrmation of accuracy with con-
ventional SMBG, and the FDA advises us-
ingthelatterfortreatmentdecisions,such
as calculating premeal insulin doses.
The clinical studies of these devices,
generally in highly selected populations,
hadprimarilybeenlimitedtoassessments
of their accuracy or to short-term trials
demonstrating reductions in the time
patients spend within hypo- and hyper-
glycemic intervals (148). A systematic re-
view of trials of the non–real-time CGM
system device suggests that it does not
lead to signiﬁcantly lower HbA1c values
compared with SMBG (149). In 2008, a
large 26-week randomized trial of 322
type 1 diabetic patients showed that
adults $25 years of age who used inten-
sive insulin therapy and real-time CGM
experienced a 0.5% reduction in HbA1c,
from approximately 7.6% to 7.1% (ap-
proximately 60 to 54 mmol/mol), com-
pared with the usual intensive insulin
therapy with SMBG (150). Sensor use in
children, teens, and adults to 24 years of
age did not lower HbA1c signiﬁcantly, and
therewasnosigniﬁcantdifferenceinhypo-
glycemia for any group. The greatest pre-
dictor of HbA1c reduction in this study
amongallage-groupswasfrequencyofsen-
sor use, which was lower in younger age-
groups. Although CGM is an evolving
technology, the emerging data suggest
that it may offer beneﬁt in appropriately
selected patients who are motivated to
wear it most of the time. CGM may be
particularlyusefulforpatientswithhypo-
glycemia unawareness and/or frequent
episodes of hypoglycemia; studies in
this area are ongoing.
2. Rationale
The ﬁrst goal for developing a reliable in
vivo continuous glucose sensor is to detect
unsuspected hypoglycemia. The impor-
tance of this goal has been increasingly
appreciated with the recognition that strict
glucose control is accompanied by a
marked increase in the risk of hypoglyce-
mia(44,147). Therefore, a sensordesigned
todetect severehypoglycemia alonewould
beofvalue.Incontrast,afull-range,reliable
continuous in vivo glucose monitor is a
prerequisite for the development of a
closed-loop pump or “artiﬁcial pancreas”
thatwouldmeasurebloodglucoseconcen-
trations and automatically adjust insulin
administration.
3. Analytical considerations
The methods to sample biological ﬂuids
in a continuous and minimally invasive
way vary among test systems. The under-
lying fundamental concept is that the
concentration of glucose in the interstitial
ﬂuid correlates with blood glucose. The
implanted sensors use multiple detection
systems, including enzyme- (usually glu-
coseoxidase),electrode-,andﬂuorescence-
based techniques. Alternatives to enzymes,
including artiﬁcial glucose “receptors,” as
glucose-recognition molecules are being
developed (151,152). Fluorescence tech-
nologies include the use of engineered
molecules that exhibit altered ﬂuores-
cence intensity or spectral characteristics
on binding glucose, or the use of com-
petitive-bindingassaysthatusetwoﬂuo-
rescent molecules in the ﬂuorescent
resonance energy transfer technique
(153–157).
4. Interpretation
The subcutaneous sensors are generally
worn for a number of days and require
calibration with SMBG readings several
times per day. A few small studies have
examined their accuracy compared with
SMBG and/or plasma glucose assays. For
the Medtronic CGMS System Gold de-
vice, the mean (SD) absolute difference
between sensor readings and blood glu-
cose readings was 15.0% (12.2%) for 735
paired samples, whereas the GlucoDay
microdialysis device (Menarini) had a
mean absolute difference of 13.6%
(10.2%) for 1,156 paired samples (158).
For both devices, accuracy was lowest in
the hypoglycemic ranges. Approximately
97% of the values for both devices were
within zones A and B of a Clarke error
grid, with none falling in zone E (158).
A study of 91 insulin-treated patients
using the DexCom device showed that
95% of 6,767 paired glucose values fell
within Clarke error grid zones A and B,
with a mean absolute difference of 21.2%
(148).
Currently, there are no analytical goals
for noninvasive and minimally invasive
glucose analyses. Such standards will
clearly need to be different for different
proposed uses. For example, the reliability,
precision, and accuracy requirements for a
glucosesensorthatislinkedtoasystemthat
automatically adjusts insulin doses will be
muchmorestringentthanthoseforasensor
designed to trigger an alarm in cases of
apparent extreme hyper- or hypoglycemia.
It seems intuitively obvious that a larger
imprecision canbe toleratedininstruments
that make frequent readings during each
hourthaninaninstrumentusedonly2or3
times per day to adjust a major portion ofa
person’s daily insulin dose.
5. Emerging considerations
With FDA approval of several self-
monitoring continuous glucose sensors,
itisanticipated that therewillbe renewed
efforts to bring other technologies for-
ward into clinical studies. Ultimately, we
shall see improved methods for noninva-
sive or minimally invasive glucose mea-
surements that will complement current
glucose self-monitoring techniques.
RECOMMENDATION: REAL-TIME CGM MAY
BE A SUPPLEMENTAL TOOL TO SMBG IN
INDIVIDUALS WITH HYPOGLYCEMIA
UNAWARENESS AND/OR FREQUENT
EPISODES OF HYPOGLYCEMIA
B( l o w ) .
RECOMMENDATION: PATIENTS REQUIRE
EXTENSIVE TRAINING IN USING THE
DEVICE. AVAILABLE DEVICES MUST BE
CALIBRATED WITH SMBG READINGS, AND
THE LATTER ARE RECOMMENDED FOR
MAKING TREATMENT CHANGES
GPP.
care.diabetesjournals.org DIABETES CARE, VOLUME 34, JUNE 2011 e71
Sacks and AssociatesNONINVASIVE GLUCOSE
ANALYSIS
1. Use
Noninvasive glucose-sensing technolo-
gies represent a group of potential ana-
lytical methods for measuring blood
glucose concentrations without implant-
ing a probe or collecting a sample of
any type. The most commonly explored
methods involve passing a selected band
of nonionizing electromagnetic radiation
(light) through a vascular region of the
body and then determining the in vivo
glucose concentration from an analysis of
the resulting light or spectrum. The dis-
tinguishing feature of this approach is a
lack of physical contact between the
sample matrix and a measurement probe.
Theonlyfunctionalinteractionisthelight
passing through the sample.
A truly noninvasive method would be
painless in operation and capable of con-
tinuous readings over time. In addition,
noninvasivesensingtechnologymaybeless
expensive to implement than existing tech-
nologiesthatdemandeitherafreshteststrip
foreachmeasurementoranewimplantable
probe that requires multiple daily calibra-
tion measurements with fresh test strips.
Furthermore, most noninvasive strategies
offer the potential for measuring multiple
analytes from a single noninvasive mea-
surement. The development of this tech-
nology isdriven by the features ofboth low
cost and painless, continuous operation
with no reagents or waste for disposal.
Reports in the peer-reviewed litera-
ture describe noninvasive measurements
based on a variety of techniques, such as
absorption spectroscopy, photoacoustic
spectroscopy, Raman scattering, static
light scattering, polarimetry, and optical
coherent tomography (159–162). Po-
tential applications include discrete home
glucose testing, continuous home glucose
monitoring, nocturnal hypoglycemia
alarm,measurementsinaphysician’sofﬁce,
point-of-care monitoring, screening for di-
abetes,andcontrolofhyperglycemiaincrit-
ically ill patients. To date, none of these
applications has been realized.
2. Rationale
Indirect and direct methods are being
developed for noninvasive glucose sens-
ing. Indirect methods rely on the effect of
in vivo glucose concentrations on a mea-
surable parameter. The classic example of
this approach is the effect of blood glu-
cose concentrations on the scattering
properties of skin (163). Changes in
blood glucose substantially affect the dif-
ference in refractive index between skin
cells and the surrounding interstitial ﬂuid
andtherebyalterthescatteringcoefﬁcient
of skin. This parameter can be measured
in a number of ways, including ocular co-
herent tomography. Skin impedance and
theaggregationproperties of erythrocytes
are other indirect approaches.
Direct methods measure a property
of the glucose molecule itself. Vibrational
spectroscopy is the primary direct method
and generally involves mid-infrared, near-
infrared, photoacoustic, or Raman scat-
tering spectroscopy. The basis of these
measurements is the unique spectral sig-
nature of glucose relative to the back-
ground tissue matrix.
Selectivity is the primary factor that
must be addressed for either indirect or
direct approaches. The lack of an isolated
sample precludes the use of physical
separations or chemical reactions to en-
hance measurement selectivity. All of the
analytical information must originate
from the noninvasive signal. Ultimately,
the success of any approach demands a
full understanding of the fundamental
basis of selectivity. To this end, basic
research efforts are paramount to estab-
lish such a level of understanding.
3. Analytical considerations
It should no longer be acceptable to
publish results that simply demonstrate
the ability to follow glucose transients
during simple glucose tolerance tests
(164). This ability is well established in
the literature for numerous approaches,
bothindirectanddirect.Infact,itisrather
easy to monitor optical changes that cor-
relate with in vivo glucose concentrations
during glucose tolerance tests. It is con-
siderably more difﬁcult, however, to
demonstrate that such measurements are
reliable and selective. Reliability and se-
lectivitymustbethefocusofthenextgen-
eration of research. Indeed, the FDA
considers all noninvasive sensing tech-
nologies to be high-risk medical devices,
and premarket approval documentation
will be required for commercialization
in the U.S. (165).
Many reports of attempts to measure
glucose noninvasively lack sufﬁcient in-
formation to judge the likelihood that
glucose is actually being measured. The
interpretation of such clinical data is
complicated by the common use of mul-
tivariate statistical methods, such as par-
tial least squares regression and artiﬁcial
neural networks. These multivariate
methods are prone to spurious correla-
tions that can generate apparently func-
tional glucose measurements in the
complete absence of glucose-speciﬁca n -
alyticalinformation(166,167).Giventhis
known limitation of these multivariate
methods, care must be used in their im-
plementation. Tests for spurious correla-
tions (168–170) must be developed and
implemented with all future clinical data
to avoid reports of false success.
Despite the limitations noted above,
real progress is being made to further the
development of noninvasive glucose-
sensing technologies (171,172).Rigorous
testing of noninvasive technologies must
be continued in concert with efforts to
understandtheunderlyingchemicalbasis
ofselectivity.Issuesofcalibrationstability
must also be investigated. Overall prog-
ress demands advances in both instru-
mentation and methods of data analysis.
For each, meaningful benchmarks must
be established to allow rigorous inter-
and intralaboratory comparisons.
GESTATIONAL DIABETES
MELLITUS
1. Use
GDM has been deﬁned as any degree of
glucose intolerance with onset or ﬁrst
recognition occurring during pregnancy
(1). After recent discussions, the Interna-
tional Association of the Diabetes and
Pregnancy Study Groups (IADPSG) rec-
ommended that high-risk women who
have diabetes established according to
standard criteria (Table 4) at their initial
prenatal visit receive a diagnosis of overt,
RECOMMENDATION: ALL PREGNANT
WOMEN NOT PREVIOUSLY KNOWN TO
HAVE DIABETES SHOULD UNDERGO
TESTING FOR GDM AT 24–28 WEEKS OF
GESTATION
A( h i g h ) .
RECOMMENDATION: NO NONINVASIVE
SENSING TECHNOLOGY IS CURRENTLY
APPROVED FOR CLINICAL GLUCOSE
MEASUREMENTS OF ANY KIND. MAJOR
TECHNOLOGICAL HURDLES MUST BE
OVERCOME BEFORE NONINVASIVE
SENSING TECHNOLOGY WILL BE
SUFFICIENTLY RELIABLE TO REPLACE
EXISTING PORTABLE METERS,
IMPLANTABLE BIOSENSORS, OR
MINIMALLY INVASIVE TECHNOLOGIES
C (very low).
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Position Statementnot gestational, diabetes (21). The
IADPSG recommendations are not iden-
tical to the criteria for nonpregnant indi-
viduals, in that an OGTT result with an
FPGvalue,7.0mmol/L(126mg/dL)and
2-h value .11.1 mmol/L (200 mg/dL) is
not called “overt diabetes.” As the preva-
lence of obesity and type 2 diabetes has
increased, the number of women with un-
diagnosed diabetes has risen (173). There-
fore, the ADA now recommends that
womenwithriskfactorsfortype2diabetes
be screened for diabetes according to stan-
darddiagnosticcriteria(Table4)attheﬁrst
prenatal visit (93). Women with diabetes
diagnosed with this approach should
receive a diagnosis of overt diabetes.
Two randomized clinical trials have
now demonstrated a beneﬁtf r o mt h e
treatment of “mild” GDM. Both studies
found that treatment of GDM can reduce
both serious adverse outcomes and the
frequency of large babies (macrosomia)
(174,175).
2. Rationale
The ADA states that because of the risks of
GDM to the mother and the neonate,
screening and diagnosis are warranted
(21). The screening and diagnostic criteria
for GDM have recently been modiﬁed ex-
tensively. The Hyperglycemia and Adverse
Pregnancy Outcome (HAPO) study was a
large (approximately 25,000 pregnant
women) prospective, multinational epide-
miologic study to assess adverse outcomes
as a function of maternal glycemia (176).
Thestudyrevealedstrong,graded,predom-
inantly linear associations between mater-
nal glycemia and primary study outcomes,
i.e.,birth weight .90th percentile, delivery
by cesarean section, clinical neonatal hypo-
glycemia, and cord serum insulin (C-
peptide) concentrations .90th percentile
of values in the HAPO study population.
Theassociationsremainstrongafteradjust-
ments for multiple potentially confounding
factors.Strongassociationswerealsofound
with infant adiposity (177), with some sec-
ondary outcomes (including risks of shoul-
der dystocia and/or birth injury), and with
preeclampsia (176). On the strength of
these results, an expert consensus panel ap-
pointed by the IADPSG recommended
“outcome based” criteria for the classiﬁca-
tionofglucoseconcentrationsinpregnancy
(178). All pregnant women not previously
knowntohavediabetesshouldbeevaluated
by a 75-g OGTT for GDM at 24–28 weeks
of gestation (178). Diagnostic cut points for
fasting, 1-h, and 2-h plasma glucose con-
centrationshavebeenestablished(Table6).
These recommendations were adopted by
the ADA in 2011 (93) and are currently un-
der consideration by the American College
of Obstetrics and Gynecology in the U.S.
and by corresponding groups in other
countries. Using the new criteria substan-
tially increases the incidence of GDM,
mainly because only one increased glucose
value is required to diagnose GDM (prior
recommendations required two increased
glucose concentrations). Treatment will re-
quire additional resources, and outcome
studies will be necessary to ascertain
whether therapy is beneﬁcial for GDM di-
agnosed with the newcriteria;however, the
two trials that focused on the treatment of
“mild GDM” (identiﬁed with the old crite-
ria)achievedanimprovement in outcomes,
with only 10%–20% of the patients requir-
ing pharmacologic treatment in addition to
medical nutritional therapy (174,175).
3. Analytical considerations
These considerations have been ad-
dressed earlier in the Glucose sections.
Given the strict cutoffs, it is very impor-
tant that close attention be paid to strin-
gent sample-handling procedures to
minimize glycolysis after phlebotomy.
4. Interpretation
The ADA previously recommended
that a “risk assessment” (based on age,
weight, past history, and so on) be
performed and that patients at average or
high risk receive a glucose-challenge test.
Several diagnostic strategies could be
used. They were a “1-step” approach, in
which an OGTT was performed initially,
or a “2-step” approach, in which an ad-
ministered 50-g oral glucose load (regard-
lessofwhetherthepatientwasfasting)was
followed by a plasma glucose measure-
ment at 1 h. A plasma glucose value
$7.8 mmol/L (140 mg/dL) indicates the
need for deﬁnitive testing with an OGTT;
however, a consensus was lacking as to
whether a 100-g or 75-g OGTT should
be performed and what cutoff values
should be used for diagnosis.
Some GDM cases may represent pre-
existing, but undiagnosed, type 2 diabe-
tes. Therefore, women with GDM should
bescreenedfordiabetes6–12weekspost-
partum according to the OGTT criteria
for nonpregnant women (Table 5) (93).
In addition, because women with GDM
are at a considerably increased risk of de-
veloping diabetes later (179), lifelong
screening for diabetes should be per-
formed at least every 3 years according
to standard criteria for nonpregnant
women (Table 4) (93).
URINARY GLUCOSE
1. Use
Semiquantitative urine glucose testing,
once the hallmark of diabetes care in the
home setting, has now been replaced by
SMBG (see above). Semiquantitative
urine glucose monitoring should be con-
sidered only for patients who are unable
or refuse to perform SMBG, because the
urine glucose concentration does not
accurately reﬂect the plasma glucose con-
centration (147,180). Notwithstanding
theselimitations,urineglucosemonitoring
is supported by the IDF in those situations
in which blood glucose monitoring is not
accessible or affordable, particularly in
resource-poor settings (23).
2. Rationale
Although urine glucose is detectable in
patients with grossly increased blood
glucose concentrations, it provides no
information about blood glucose concen-
trations below the variable renal glucose
Table 6—Screening for and diagnosis of
GDM
Glucose
measure
Glucose
concentration
threshold,
mmol/L (mg/dL)
a
Percentage
.threshold
(cumulative)
b
FPG 5.1 (92) 8.3%
1-h PG 10.0 (180) 14.0%
2-h PG 8.5 (153) 16.1%
c
aOne or more of these values from a 75-g OGTT
must be equaled or exceeded for the diagnosis of
GDM.
bCumulative proportion of HAPO cohort
equalingorexceedingthosethresholds.
cInaddition,
1.7% of participants in the initial cohort were un-
blinded because of an FPG value .5.8 mmol/L (105
mg/dL) or a 2-h OGTT value .11.1 mmol/L (200
mg/dL), bringing the total to 17.8%.
RECOMMENDATION: GDM SHOULD BE
DIAGNOSED BY A 75-G OGTT ACCORDING
TO THE IADPSG CRITERIA DERIVED FROM
THE HAPO STUDY
A( m o d e r a t e ) .
RECOMMENDATION: SEMIQUANTITATIVE
URINE GLUCOSE TESTING IS NOT
RECOMMENDED FOR ROUTINE CARE OF
PATIENTS WITH DIABETES MELLITUS
B( l o w ) .
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Sacks and Associatesthreshold [approximately 10 mmol/L
(180 mg/dL)]. This fact alone limits its
usefulness for monitoring diabetes under
modern care recommendations. Semi-
quantitative urine glucose tests also cannot
distinguish between euglycemiaandhypo-
glycemia.Furthermore,theextenttowhich
thekidneyconcentratestheurinewillaffect
urine glucose concentrations, and only
mean glucose values between voidings are
reﬂected. These facts further minimize the
value of urine glucose measurements.
3. Analytical considerations
Semiquantitative test-strip methods that
use reactions speciﬁc for glucose are
recommended. Commercially available
strips use the glucose oxidase reaction
(181). Test methods that detect reducing
substancesarenotrecommendedbecause
they are subject to numerous interfer-
ences, including numerous drugs and non-
glucose sugars. When used, single voided
urine samples are recommended (147).
4. Interpretation
Becauseofthelimiteduseofurineglucose
measurements, semiquantitative speciﬁc
reaction–based test-strip methods are ad-
equate.
KETONE TESTING
1. Use
The ketone bodies acetoacetate (AcAc),
acetone, and b-hydroxybutyric acid
(bHBA) are catabolic products of free fatty
acids.Measurementsofketonesinurineand
bloodarewidelyusedinthemanagementof
patients with diabetes as adjuncts for both
diagnosis and ongoing monitoring of DKA.
Measurements of ketone bodies are rou-
tinely performed, both in an ofﬁce/hospital
setting and by patients at home. The ADA
recommends that ketosis-prone patients
with diabetes check urine or blood ketones
in situations characterized by deterioration
in glycemic control in order to detect and
preemptthedevelopmentofDKA(21,182).
2. Rationale
Ketonebodiesareusuallypresentinurine
andblood,butinverylowconcentrations
(e.g.,totalserumketones,,0.5mmol/L).
Increased ketone concentrations detected
inpatients withknowndiabetesorinpre-
viously undiagnosed patients presenting
with hyperglycemia suggest impending
orestablishedDKA,amedicalemergency.
The two major mechanisms for high ke-
tone concentrations in patients with dia-
betes are increased production from
triglycerides and decreased utilization in
the liver—both of which are due to an
absolute or relative insulin deﬁciency
and increased counter-regulatory hor-
mones, including cortisol, epinephrine,
glucagon, and growth hormone (183).
The principal ketone bodies bHBA
and AcAc are typically present in approx-
imately equimolar amounts. Acetone,
usually present in only small quantities,
is derived from spontaneous decarboxyl-
ation of AcAc. The equilibrium between
AcAc and bHBA is shifted towards bHBA
formation in any condition that alters the
redox state of hepatic mitochondria to in-
crease NADH concentrations, such as
hypoxia, fasting, metabolic disorders (in-
cluding DKA), and alcoholic ketoacidosis
(184–186). Thus, assay methods for ke-
tones that do not include bHBA measure-
ment may provide misleading clinical
information by underestimating total ke-
tone body concentration (187).
3. Analytical considerations
A. Urine ketones
1. Preanalytical. The concentrations of
ketonesintheurineofhealthyindividuals
are below the detection limits of commer-
cially available testing materials. False-
positive results have been reported with
highly colored urine and in the presence
of several sulfhydryl-containing drugs,
including angiotensin-converting en-
zyme inhibitors (188). Urine test reagents
deteriorate with exposure to air, giving
false-negative readings; therefore, testing
materialshould be stored in tightly sealed
containers and discarded after the expira-
tion date on the manufacturer’s label
(189). False-negative readings have also
been reported with highly acidic urine
samples, such as after large intakes of
ascorbic acid. Loss of ketones from urine
attributable to microbial action can also
cause false-negative readings. Because ac-
etone is a highly volatile substance, sam-
ples should be kept in a closed container.
For point-of-care analyses in medical fa-
cilities and for patients in the home set-
ting, control materials (that give both
negative and positive readings) are not
commercially available but would be de-
sirable to ensure accuracy of test results.
2.Analytical.Severalassayprincipleshave
been described. Most commonly used is
the colorimetric reaction that occurs be-
tween AcAc and nitroprusside (sodium
nitroferricyanide) to produce a purple
color (181). This method is widely avail-
able in the form of dipsticks and tablets
and is used to measure ketones in both
the urine and blood (either serum or
plasma). Several manufacturers offer dip-
sticks for measuring glucose and ketones.
A combination dipstick is necessary only
if the patient monitors urine glucose in-
stead of or in addition to blood glucose.
The nitroprusside method measures only
AcAc unless the reagent contains glycine,
in which case acetone is also measured.
The nitroprusside-containing reagent is
much more sensitive to AcAc than ace-
tone with respect to color generation. Im-
portantly, this reagent cannot be used to
measure bHBA (181).
B. Blood ketones
1. Preanalytical. Serum/plasma ketones
can be measured with the tablets or dip-
sticks routinely used for urine ketone
measurements. Although samples can be
diluted with saline to “titer” t h ek e t o n ec o n -
centration (results are typically reported as
“positive at a 1/x dilution”), bHBA, the pre-
dominant ketone body in DKA, is not de-
tected, as with urine ketone testing.
For speciﬁc bHBA measurements,
sample requirements differ among meth-
ods, as is described below. In general,
blood samples can be collected into tubes
containing heparin, EDTA, ﬂuoride, cit-
rate, or oxalate. Ascorbic acid interferes
with some assay methods.AcAcinterferes
with some assay methods unless the sam-
plesarehighlydilute.Samplestabilitydif-
fers among methods, but whole-blood
samples are generally stable at 4°C for
up to 24 h. Serum/plasma samples are
stable for up to 1 week at 4°C and for at
least several weeks at 220°C (long-term
stability data are not available for most
assay methods).
2. Analytical. Although several different
assay methods (e.g., colorimetric, gas
chromatography, capillary electrophore-
sis, and enzymatic) have been described
forbloodketones,includingspeciﬁcmea-
surement of bHBA, enzymatic methods
appear to be the most widely used for
the quantiﬁcation of bHBA for routine
clinical management (190–192). The
principle of the enzymatic methods is
that b-hydroxybutyrate dehydrogenase
in the presence of NAD
1 converts bHBA
to AcAc and NADH. Under alkaline con-
ditions (pH 8.5–9.5), the reaction favors
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NADH produced can be quantiﬁed spec-
trophotometrically (usually kinetically)
with the use of a peroxidase reagent.
Most methods permit the use of whole-
blood, plasma, or serum samples (re-
quired volumes are generally #200 mL).
Somemethodspermittheanalysisofmul-
tipleanalytes;thesemethodsaredesigned
for point-of-care testing. Several methods
are available as handheld meters, which
have been FDA cleared for both laboratory
useandhomeusebypatients.Thesemeth-
odsusedry-chemistryteststripstowhicha
drop of whole blood, serum, or plasma is
added. Results are displayed on the instru-
ments within approximately 2 min.
4. Interpretation
A. Urine ketone measurements. The
presenceofpositiveurineketonereadings
in a patient with known diabetes or a
patient not previously diagnosed with
diabetes but who presents with typical
symptoms of diabetes and hyperglycemia
suggests the possibility of impending or
established DKA. Although DKA is most
commonly associated with type 1 diabe-
tes, it may occur rarely in type 2 diabetic
patients (193). Patients with alcoholic
ketoacidosis will have positive urine
ketone readings, but hyperglycemia is
not usually present. Positive urine ketone
readings are found in up to 30% of ﬁrst
morning urine samples from pregnant
women (with or without diabetes), dur-
ing starvation, and after hypoglycemia
(187).
B. Blood ketone measurements. Blood
ketone measurements that rely on the
nitroprusside reaction should be used
with caution for DKA diagnosis, because
theresultsdonotquantifybHBA,thepre-
dominantketoneinDKA. The test should
not be used to monitor the course of
therapy, because AcAc and acetone may
increase as bHBA decreases during suc-
cessful therapy (147,183–187). Blood
ketone measurements that measure bHBA
speciﬁcally are useful for both the diag-
nosis and ongoing monitoring of DKA
(194–196). Reference intervals for bHBA
differ among assay methods, but concen-
trations in healthy individuals who have
fasted overnight are generally ,0.5
mmol/L. Patients with well-documented
DKA [serum CO2 ,17 mmol/L, arterial
pH ,7.3, plasma glucose .14.9 mmol/L
(250 mg/dL)] generally have bHBA con-
centrations .2 mmol/L.
5. Emerging considerations
Further studies are needed to determine
whether blood ketone measurements by
patients with diabetes are preferable (e.g.,
better accepted by patients, more prompt
diagnosis of DKA) to urine ketone meas-
urements. Studies are necessary to evalu-
ate whether the test offers any clinical
advantage over more traditional manage-
ment approaches (e.g., measurements of
serum CO2, anion gap, or pH).
HbA1c
1. Use
Measurement of glycated proteins, pri-
marily HbA1c, is widely used for routine
monitoring of long-term glycemic status
in patients with diabetes. [The terms “gly-
cated hemoglobin,”“ glycohemoglobin,”
“glycosylated” (which should not be
used), “glucosylated hemoglobin,”“ HbA1,”
and “HbA1c” have all been used to refer to
hemoglobinthathasbeenmodiﬁedbythe
nonenzymatic addition of glucose. These
terms are not interchangeable, however.
The current acceptable term for glycation
of hemoglobin in general is “glycated he-
moglobin” (GHb). HbA1c is the speciﬁc
glycated species that is modiﬁed by glu-
cose on the N terminus of the hemoglobin
b chain. “HbA1c” is also the internation-
ally accepted term for reporting all GHb
results. Assay methods that measure to-
tal GHbs (e.g., boronate afﬁnity meth-
ods) should be calibrated to report an
equivalent HbA1c a n db er e p o r t e da s
HbA1c for purposes of harmonization of
results. HbA1 is composed of HbA1a,
HbA1b,andHbA1candshouldnotbemea-
sured or reported. The term “A1C test” is
used by the ADA in place of HbA1c to fa-
cilitate communication with patients. As
d e s c r i b e di nt h et e x t ,m o s to ft h ec l i n i -
cal-outcome data that are available for
theeffectsofmetabolic controloncompli-
cations(atleastfortheDCCTandUKPDS)
involved the use of assay methods that
quantiﬁed HbA1c. In this report, we use
theabbreviationGHbtoincludeallforms
of glycated hemoglobin.] HbA1c is used
both as an index of mean glycemia and
as a measure of risk for the development
of diabetes complications (147,197).
HbA1c testing and maintenance of speci-
ﬁed concentrations during pregnancy in
patients with preexisting type 1 or type 2
diabetes are important for maximizing
thehealthofthenewbornand decreasing
perinatal risks for the mother. Speciﬁ-
cally, stringent control of HbA1c values
during pregnancy decreases the risk of
congenital malformations, large-for-date
infants, and the complications of preg-
nancyanddeliverythatcanotherwiseoc-
curwhenglycemiccontrolisnotcarefully
managed(198).Arecentconsensusstate-
ment (198) recommends an HbA1c value
of ,6% (42 mmol/mol) in these patients
if it can be achieved without excessive
hypoglycemia. HbA1c is also being used
increasingly by quality-assurance pro-
g r a m st oa s s e s st h eq u a l i t yo fd i a b e t e s
care (e.g., requiring that healthcare pro-
viders document the frequency of HbA1c
testing in patients with diabetes and the
proportion of patients with HbA1c values
below a speciﬁed value) (199,200).
TheADAandotherorganizationsthat
have addressed this issue recommend
HbA1c measurement in both type 1 and
type 2 diabetic patients to document the
degree of glycemic control and to assess
response to therapy (21,93,201). The
ADA has recommended speciﬁc treat-
ment goals for HbA1c on the basis of re-
sults from prospective randomized
clinical trials, most notably the DCCT
for type 1 diabetes (44,197) and the
UKPDS for type 2 diabetes (46). These
trials have documented the relationship
between glycemic control (as quantiﬁed
by longitudinal HbA1c measurements)
and the risks for the development and
progression of chronic complications of
diabetes. Because different GHb assays
can produce different GHb values, the
ADA recommends that laboratories use
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ﬁed as traceable to the DCCT GHb refer-
ence (21,187); these results are reported
as HbA1c. The ADA recommends that in
general an HbA1c target of ,7% (53
mmol/mol) is desirable for nonpregnant
adults, with higher values recommended
for children and adolescents (21). HbA1c
goals should be individualized according
tothepotentialforbeneﬁtwithregardto
long-term complications and be bal-
anced against the increased risk for the
hypoglycemia that attends intensive
therapy. For selected individual pa-
tients, more-stringent targets could be
suggested, provided that this goal can
be achieved without substantial hypo-
glycemia or other adverse effects of
treatment. Such patients might include
t h o s ew i t has h o r td u r a t i o no fd i a b e t e s ,
alonglifeexpectancy,andnosigniﬁcant
cardiovascular disease (93). Conversely,
higher HbA1c goals should be chosen
for patients with a history of severe
hypoglycemia, a limited life expectancy,
advanced microvascular or macrovascular
complications, or extensive comorbid con-
ditions. Other clinical organizations recom-
mend similar HbA1c targets, which range
from 6.5% to 7% (48 to 53 mmol/mol)
(53,202).
2. Rationale
Glycated proteins are formed posttransla-
tionally from the slow, nonenzymatic
reaction between glucose and free amino
groupsonproteins(203).ForHb,therate
of GHb synthesis is principally a function
of the glucose concentration to which the
erythrocytes are exposed, integrated over
the time of exposure. GHb is a clinically
useful index of mean glycemia during the
preceding 120 days, the average life span
of erythrocytes (147,203–206). Several
studies have demonstrated a close math-
ematicalrelationshipbetweenHbA1ccon-
centration and mean glycemia, which
should allow the expression of HbA1c as
an estimated average glucose (eAG) con-
centration (205,207–209). Analogous to
Hb (in erythrocytes), serum proteins be-
come glycated. Commercial assays are
available that measure total glycated pro-
tein (termed fructosamine) or glycated al-
bumin in the serum. The concentrations
of these glycated proteins also reﬂect
mean glycemia, but over a much shorter
time (15–30 days) than GHb (60–120
days) (147,203–206,210,211). The clini-
cal utility of glycated proteins other than
Hb has not been clearly established, how-
ever, and there is no convincing evidence
that relates their concentrations to the
chronic complications of diabetes
(147,187).
3. Analytical considerations
Approximately 100 different GHb assay
methods are in current use. They range
from low-throughput research laboratory
component systems and manual mini-
column methods to high-throughput
automated systems dedicated to HbA1c
measurements. Most methods can be
classiﬁed into one of two groups ac-
cording to assay principle (147,181,
204). The ﬁrst group includes methods
that quantify GHb on the basis of charge
differences between glycated and nongly-
cated components. Examples include
cation-exchange chromatography and
agar-gel electrophoresis. The second
group includes methods that separate
components on the basis of structural
differences between glycated and nongly-
cated components. Examples include
boronate afﬁnity chromatography and
immunoassay. Most charge-based and
immunoassay methods quantify HbA1c,
which is deﬁned as HbA with glucose at-
tached to the N-terminal valine of one or
both b chains. Other methods quantify
“total glycated hemoglobin,” which in-
cludes both HbA1c and other Hb–glucose
adducts (e.g., glucose–lysine adducts and
glucose–a-chain N-terminal valine ad-
ducts). Generally, the results of methods
that use different assay principles show
excellent correlation, and there are no
convincing data to show that any method
typeoranalyteisclinicallysuperiortoany
other. The GHb results reported for the
same blood sample could differ consider-
ably among methods, however, unless
theyhavebeenstandardizedtoacommon
reference [e.g., without standardization,
the same blood sample could be read as
7% (42 mmol/mol) in one laboratory and
9% (75 mmol/mol) in another] (53,147,
204,212–215).
In 1996, the NGSP was initiated to
standardize GHb test results among labo-
ratories to DCCT-equivalent values (215).
The rationale for standardizing GHb test
results to DCCT values was that the
DCCT had determined the relationship be-
tween the results obtained for a speciﬁc
GHb test (HbA1c) and long-term complica-
tions in patients with type 1 diabetes
(44,147,187). The NGSP was developed
under the auspices of the American Associ-
ation for Clinical Chemistry (AACC) and is
endorsed by the ADA, which recommends
that laboratories use only GHb methods
that have passed certiﬁcation testing by
the NGSP (21,147). In addition, the ADA
recommends that all laboratories perform-
ing GHb testing participate in the CAP
proﬁciency-testingsurveyforHbA1c,which
uses fresh whole-blood samples (216).
The NGSP Laboratory Network
includes a variety of certiﬁed assay meth-
ods, each calibrated to the DCCT refer-
ence. The DCCT reference is an HPLC
cation-exchange method that quantiﬁes
HbA1c; this method is a CLSI-designated
comparison method (217). The assay
method has been used since 1978 and
has demonstrated good long-term preci-
sion (between-run CVs are consistently
,3%) (216). Secondary reference labora-
tories in the Network interact with man-
ufacturersofGHbmethodstoassistthem,
ﬁrst in calibrating their methods and then
in providing comparison data for certiﬁ-
cation of traceability to the DCCT. Certi-
ﬁcation is valid for 1 year. An important
adjunct to the program is the HbA1c
proﬁciency-testing survey administered
by CAP. Since 1996 (starting with a pilot
projectincluding500laboratoriesandex-
panded to all laboratories in 1998), the
survey has used fresh whole-blood sam-
ples with NGSP-assigned target values.
Since initiation of the NGSP in 1996,
the survey has documented a steady im-
provement in comparability of GHb val-
ues among laboratories, both within and
between methods (216,218). In 2007,
CAP initiated “accuracy-based” grading
with the value of each sample assigned
b yt h eN G S PN e t w o r k .T h eo b j e c t i v ei s
RECOMMENDATION: LABORATORIES
SHOULD USE ONLY HbA1c ASSAY METHODS
THAT ARE CERTIFIED BY THE NATIONAL
GLYCOHEMOGLOBIN STANDARDIZATION
PROGRAM (NGSP) AS TRACEABLE TO THE
DCCT REFERENCE. THE MANUFACTURERS
OF HbA1c ASSAYS SHOULD ALSO SHOW
TRACEABILITY TO THE IFCC
REFERENCE METHOD
GPP.
RECOMMENDATION: LABORATORIES THAT
MEASURE HbA1c SHOULD PARTICIPATE
IN A PROFICIENCY-TESTING PROGRAM,
SUCH AS THE COLLEGE OF AMERICAN
PATHOLOGISTS (CAP) HbA1c SURVEY,
THAT USES FRESH BLOOD SAMPLES
WITH TARGETS SET BY THE NGSP
LABORATORY NETWORK
GPP.
e76 DIABETES CARE, VOLUME 34, JUNE 2011 care.diabetesjournals.org
Position Statementto reduce bias and imprecision among as-
says. The NGSP Web site (http://www.
ngsp.org) provides detailed information
on thecertiﬁcation process and maintains
a listing of certiﬁed assay methods (up-
dated monthly) and factors that are
known tointerferewith speciﬁcmethods.
In 1997, the IFCC formed a commit-
t e et od e v e l o pah i g h e r - o r d e rr e f e r e n c e
methodandreferencematerialsforHbA1c
analysis; the method was approved in
2001 (219,220). The analysis is per-
formed by cleaving Hb with endopro-
teinase Glu-C and separating the resulting
glycated and nonglycated N-terminal
b-chain hexapeptides by HPLC (220).
Thehexapeptidesarequantiﬁedwithelec-
trospray ionization mass spectrometry
or capillary electrophoresis. The two
methods use the same primary reference
materials, and the results are essentially
identical. HbA1c is measured as the ratio
of the glycated N-terminal peptide to the
nonglycated N-terminal peptide and is re-
ported in millimoles of deoxyfructosyl Hb
per mole of Hb. Of note, preparing and
measuring samples with this method is
laborious, very expensive, and time-
consuming. The method was never envi-
sioned as a practical means of assaying
clinical samples. It will only be used by
manufacturers to standardize the assays.
Like the NGSP, the IFCC has established
a network of laboratories (221) (11 at the
time of writing). The IFCC offers manu-
facturers calibrators and controls as well
as a monitoring program (221). Unlike
the NGSP, the IFCC network does not
have a certiﬁcation program.
Ac o m p a r i s o no fH b A 1c results
obtained with pooled blood samples in
the IFCC and NGSP (DCCT-aligned)
networks has revealed a linear relation-
ship (termed the “master equation”):
NGSP% 5 (0.915 x IFCC%) 1 2.15
(220). Although the clinical values ob-
tained with assays standardized with the
new IFCC method correlate tightly with
NGSP values, the absolute HbA1c values
reported differ by 1.5%–2.0% HbA1c.
Concern regarding the clinical impact of
changing patients’ HbA1c values led in
2007 to an agreement between the IFCC
and the major diabetes organizations to
report IFCC HbA1c results (in millimoles
per mole) as the equivalent NGSP DCCT-
aligned result (a percentage based on the
master equation) and as a calculated eAG
based on the A1c-Derived Average Glu-
cose (ADAG) study (209,222). In the re-
vised agreement, published in 2010
(223), both NGSP and IFCC units were
recommended, but the decision to report
eAG was left to the discretion of individ-
ual countries. Notwithstanding the agree-
ment, it appears unlikely that universal
reporting of HbA1c will be adopted; how-
ever, the master equation allows conver-
sion between IFCC and NGSP numbers.
A. Preanalytical
1. Patient variables. HbA1c results are not
affectedsigniﬁcantlybyacuteﬂuctuations
in blood glucose concentrations, such as
thoseoccurringwithillnessoraftermeals;
however, age and race reportedly inﬂu-
ence HbA1c. Published data show age-
related increases in HbA1c values of
approximately 0.1% per decade after age
30 years (224,225). Careful phenotyping
of individuals with OGTT supports an in-
crease in HbA1c with age, even after re-
moving from the study population
patients with otherwise undiagnosed di-
abetes and personswith impaired glucose
tolerance (224). The clinical implications
ofthesmall,butstatisticallysigniﬁcant,pro-
gressive increase in “normal” HbA1c levels
with aging remain to be determined (226).
The effects of race on HbA1c values
are controversial. Several studies have
suggested a relatively higher HbA1c in Af-
rican American and Hispanic populations
thaninCaucasianpopulationsatthesame
level of glycemia (225,227,228). The ac-
cumulated evidence suggests that there
are differences in HbA1c among racial
groups; however, the measurement of
chronic glucose concentrations in these
studies has not been sufﬁciently frequent
tocaptureadequatelytheactualmeangly-
cemia. Moreover, it is not clear that the
differences in HbA1c have clinical signiﬁ-
cance. A recent analysis of 11,092 adults
showed that blacks had mean HbA1c val-
ues 0.4% higher than whites (229);
however, race did not modify the associ-
ation between HbA1c concentration and
adversecardiovascularoutcomesordeath
(229). The ADAG study, which included
frequent glucose measurements, did not
show a signiﬁcantly different relationship
betweenthecalculatedmeanglucosecon-
centration during 3 months and the
HbA1c value at the end of the 3 months
for Africans/African Americans and Cau-
casians. The relatively small size of the
African/African American population,
however, limits the interpretation of this
ﬁnding (209).
Any condition that shortens erythro-
cyte survival or decreases mean erythro-
cyte age (e.g., recovery from acute blood
loss, hemolytic anemia) falsely lowers
HbA1c test results, regardless of the assay
method (147). Vitamins C and E are re-
ported to falsely lower test results, possi-
bly by inhibiting Hb glycation (230,231).
Iron deﬁciency anemia increases test re-
sults(232).Foodintakehasnosigniﬁcant
effect on test results. Hypertriglyceride-
mia, hyperbilirubinemia, uremia, chronic
alcoholism, chronic ingestion of salicy-
lates, and opiate addiction reportedly in-
terfere with some assay methods, falsely
increasing results (204,233).
Several Hb variants (e.g., Hbs S, C, D,
and E) and chemically modiﬁed Hb de-
rivatives interfere with some assay meth-
ods [independently of any effects due to
shortened erythrocyte survival (234–
236); for a review, see (233)]. Depending
on the particular hemoglobinopathy and
assay method, results can be either falsely
increased or falsely decreased. Some
methods may give a value in the reference
interval for a nondiabetic individual with
an Hb variant, but that is no assurance
that no interference is present. The inter-
ference may be subtle in the reference in-
terval but may increase steadily with
increasing HbA1c. Boronate afﬁnity chro-
matography assay methods are generally
consideredtobelessaffectedbyHbvariants
than other methods. In some instances,
such as with most cation-exchange HPLC
methods, manual inspection of chromato-
gramsoranautomatedreportbythedevice
can alert the laboratory to the presence of
either a variant or a possible interference.
If an appropriate method is used, HbA1c
can be measured accurately in the vast ma-
jority of individuals heterozygous for Hb
variants (for a summary of published stud-
ies, see http://www.ngsp.org). If altered
erythrocyte turnover interferes with the re-
lationshipbetweenmeanbloodglucoseand
HbA1c values, or if a suitable assay method
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alternative non–Hb-based methods for as-
sessing long-term glycemic control (such as
fructosamine assay) may be useful (233).
Given that interferences are method
speciﬁc, product instructions from the
manufacturer should be reviewed before
the HbA1c assay method is used. A list
of interfering factors for speciﬁc assays is
maintained on the NGSP Web site (http://
www.ngsp.org). In selecting an assay
method,alaboratoryshouldconsiderchar-
acteristics of the patient population served
(e.g., a high prevalence of Hb variants).
2. Sample collection, handling, and storage.
Blood can be obtained by venipuncture
or by ﬁnger-stick capillary sampling
(237,238). Blood tubes should contain
the anticoagulant speciﬁed by the manu-
facturer of the HbA1c assay method
(EDTA can be used unless the manufac-
turer speciﬁes otherwise). Sample stabil-
ity is assay method speciﬁc (239,240). In
general, whole-blood samples are stable for
up to 1 week at 4°C (240). For most meth-
ods, whole-blood samples stored at 270°C
or colder are stable over the long term (at
least1year),but samplesarenot asstableat
220°C. Improper handling of samples,
such as storage at high temperatures, can
introduce large artifacts that may not be de-
tectable, depending on the assay method.
Manufacturershaveintroducedanum-
berofconvenientblood-collectionsystems,
including ﬁlter paper and small vials con-
taining stabilizing/lysing reagent (241–
243). These systems are designed for ﬁeld
collectionofsamplesandroutinemailingto
the laboratory and are generally matched
with speciﬁc assay methods. They should
beusedonlyifstudieshavebeenperformed
to establish the comparability of test results
for these collection systems with standard
sample-collection and handling methods
for the speciﬁc assay method used.
B. Analytical
1. Performance goals and quality control.
Several expert groups have presented rec-
ommendations for assay performance.
Early reports recommended that the
interassay CV be ,5% at normal and di-
abetic GHb concentrations (244). Subse-
quent reports have suggested lower CVs
[e.g., intralaboratory CVs ,3% (245) or
,2% (246), and interlaboratory CVs
,5% (245)]. Intraindividual CVs for
healthy persons are very small (,2%),
and many current assay methods can
achieve intralaboratory and interlabora-
tory CVs of ,2% and ,3%, respectively
(247). A recent statistical analysis calcu-
lated appropriate goals for HbA1c assay
performance (218). If the reference
change value (also termed “critical differ-
ence”) is used, an analytical CV #2% will
produce a 95% probability that a differ-
enceof$0.5%HbA1cbetweensuccessive
patient samples is due to a signiﬁcant
change in glycemic control [when HbA1c
is 7% (53 mmol/mol)]. In addition, if a
method has no bias, a CV of 3.5% is nec-
essary to have 95% conﬁdence that the
HbA1c result for a patient with a “true”
HbA1c of 7% (53 mmol/mol) will be be-
tween 6.5% and 7.5% (between 48 and
58 mmol/mol) (218). We recommend
an intralaboratory CV ,2% and an in-
terlaboratory CV ,3.5%. For a single
method,thegoalshouldbeaninterlabor-
atory CV ,3%.
A laboratory should include two
control materials with different mean
values (high and low) at both the begin-
ning and the end of each day’s run. Fro-
zen whole-blood controls stored in
single-use aliquots at 270°C or colder
are ideal and are stable for months or
even years, depending on the assay
method. Lyophilized controls are com-
mercially available but, depending on
the assay method, may show matrix ef-
fects when new reagents or columns are
introduced. We recommend that a labo-
ratory consider using both commercial
and in-house controls to optimize per-
formance monitoring.
2. Reference intervals. A laboratory should
determine its own reference interval
according to CLSI guidelines (CLSI
Document C28A), even if the manufac-
turer has provided one. Nondiabetic test
individuals should be nonobese, have an
FPG concentration ,5.6 mmol/L (100
mg/dL), and, ideally, have a 2-h post-
OGTT plasma glucose value of ,11.1
mmol/L (200 mg/dL). For NGSP-certiﬁed
assay methods, reference intervals should
not deviate substantially (e.g., .0.5%)
from 4%–6% (20–42 mmol/mol). Note
that treatment target values recom-
mended by the ADA and other clinical
organizations, not reference intervals,
are used to evaluate metabolic control in
patients.
3. Out-of-range samples. A laboratory
shouldrepeattestingforallsampleresults
below the lower limit of the reference in-
terval, and if these results are conﬁrmed,
the physician should be informed to de-
termine whether the patient has a variant
Hb or shows evidence of erythrocyte de-
struction. If possible, the repeat HbA1c
measurement should be performed
with a method based on an analytical
principle that is different from the initial
assay. In addition, samples with results
.15% HbA1c (140 mmol/mol) should
be assayed a second time; if the results are
conﬁrmed, the possibility of an Hb variant
shouldbeconsidered(233).Anyresultthat
does not correlate with the clinical impres-
sion should also be investigated.
4. Removal of labile GHb. The formation
of HbA1c involves an intermediate Schiff
base, which is called “pre-A1c” or “labile
A1c” (248).ThisSchiffbase isformedrap-
idly with hyperglycemia and can interfere
withsomeHbA1cassaymethodsifitisnot
completely removed or separated. Most
currently available automated assays ei-
ther remove the labile pre-HbA1c during
the assay process or do not measure the
labile product.
4. Interpretation
A. Laboratory–physician interactions.
A laboratory should work closely with
physicians who order HbA1c testing.
Proper interpretation of test results re-
quires an understanding of the assay
method, including its known interfer-
ences. For example, if the assay method
is affected by hemoglobinopathies (inde-
pendently of any shortened erythrocyte
survival) or uremia, the physician should
be made aware of this interference.
An important advantage of using
an NGSP-certiﬁed method is that the
RECOMMENDATION: SAMPLES WITH HbA1c
RESULTS BELOW THE LOWER LIMIT OF
THE REFERENCE INTERVAL OR >15%
HbA1c SHOULD BE VERIFIED BY REPEAT
TESTING
B( l o w ) .
RECOMMENDATION: HbA1c VALUES THAT
ARE INCONSISTENT WITH THE CLINICAL
PRESENTATION SHOULD BE
INVESTIGATED FURTHER
GPP.
RECOMMENDATION: DESIRABLE
SPECIFICATIONS FOR HbA1c
MEASUREMENT ARE AN
INTRALABORATORY CV ,2% AND AN
INTERLABORATORY CV ,3.5%. AT LEAST
TWO CONTROL MATERIALS WITH
DIFFERENT MEAN VALUES SHOULD BE
ANALYZED AS AN INDEPENDENT MEASURE
OF ASSAY PERFORMANCE
B( l o w ) .
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mation relating HbA1c test results to
both mean glycemia and outcome risks
as deﬁn e di nt h eD C C Ta n dU K P D S
(44,147,187). This information is avail-
able on the NGSP Web site. For example,
each 1% (approximately 11 mmol/mol)
change in HbA1c is related to a change in
the mean plasma glucose concentration of
approximately1.6mmol/L(29mg/dL).Re-
porting HbA1c results with a calculated
eAGwilleliminatetheneedforhealthcare
providers or patients to perform these
calculations themselves. The equation
generated by the ADAG study is the
m o s tr e l i a b l et od a t e( 2 0 9 ) .
Some evidence suggests that imme-
diate feedback of HbA1c test results to pa-
tients at the time of the clinic visit leads to
an improvement in their long-term glyce-
mic control (249,250). Not all publica-
tions have supported this observation
(251), however, and additional studies
are needed to conﬁrm these ﬁndings be-
fore this strategy can be generally recom-
mended. It is possible to achieve the goal
of having HbA1c test results available at
the timeof the clinic visit by either having
thepatientsendin ablood sampleshortly
before the scheduled clinic visit or
having a rapid-assay system convenient
to the clinic.
B. Clinical application
1. Treatment goals. HbA1c measurements
are now a routine component of the clin-
ical management of patients with diabe-
tes. Principally on the basis of the DCCT
results, the ADA has recommended that a
primarygoaloftherapybeanHbA1cvalue
,7% (53 mmol/mol) (21). Lower targets
maybeconsideredforindividualpatients,
e.g., in diet-treated type 2 diabetes. Other
major clinical organizations have recom-
mended similar targets (53); however,
recent studies that used multiple medica-
tions to treat type 2 diabetes and aimed
for HbA1c concentrations ,6.5% (48
mmol/mol) have not demonstrated con-
sistent beneﬁts and failed to observe any
beneﬁt with regard to macrovascular dis-
ease, compared with interventions that
achieved HbA1c values 0.8% to 1.1%
higher (50–52). The ACCORD (Action
to Control Cardiovascular Risk in Dia-
betes) study demonstrated increased
mortality with very intensive diabetes
therapy [HbA1c, 6.4% vs. 7.5% (46 vs.
58 mmol/mol)]. These HbA1c values ap-
ply only to assay methods that have been
certiﬁed as traceable to the DCCT refer-
ence, with a reference interval of approxi-
mately4%–6%HbA1c(20–42 mmol/mol).
In the DCCT, each 10% reduction in
HbA1c (e.g., 12% vs. 10.8% or 8% vs.
7.2%) was associated with an approxi-
mately 45% lower risk for the progression
of diabetic retinopathy (42). Comparable
risk reductions were found in the UKPDS
(197). Also of note is that decreases in
HbA1c were associated in the DCCT and
UKPDS with an increased risk for severe
hypoglycemia.
2.Testingfrequency.Thereisnoconsensus
on the optimal frequency of HbA1c test-
ing. The ADA recommends (21), “For
any individual patient, the frequency of
A1C testing should be dependent on the
clinical situation, the treatment regimen
used, and the judgment of the clinician.”
In the absence of well-controlled studies
that suggest a deﬁnite testing protocol,
expert opinion recommends HbA1c test-
ing “at least two times a year in patients
who are meeting treatment goals (and
who have stable glycemic control) ...
and quarterly in patients whose therapy
haschangedorwhoare notmeeting glyce-
mic goals” (21). These testing recommen-
dations are for nonpregnant patients with
eithertype1ortype2diabetes.Inaddition,
allpatientswithdiabeteswhoareadmitted
to a hospital should have HbA1c measured
if the results of testing in the previous 2–3
months are not available (21). Diabetes
quality-assurance programs [e.g., Provider
Recognition Program and HEDIS (Health-
care Effectiveness Data and Information
Set) (199,200)] have generally required
documentation of the percentage of dia-
betic patients who have had at least one
HbA1c measurement during the preceding
year. Studies have established that serial
HbA1c measurements (quarterly for 1 year)
produce large improvements in HbA1c val-
ues in patients with type 1 diabetes (252).
3. Interpretation. HbA1c values in patients
with diabetes constitute a continuum.
They range from within the reference in-
terval in a small percentage of patients
whose mean plasma glucose concentra-
tions are close to those of nondiabetic in-
dividuals, to markedly increased values
(e.g., two- to threefold increases in some
patients) that reﬂect an extreme degree of
hyperglycemia. A proper interpretation of
HbA1c test results requires that physi-
cians understand the relationship be-
tween HbA1c values and mean plasma
glucose, the kinetics of HbA1c,a n ds p e -
ciﬁc assay limitations/interferences (147).
Small changes in HbA1c (e.g., 60.3%
HbA1c) over time may reﬂect assay impre-
cisionratherthanatruechangeinglycemic
status (218).
5. Emerging considerations
A.UseofHbA1cfordiabetesscreening/
diagnosis. The role of HbA1c in the diag-
nosis of diabetes has been considered for
RECOMMENDATION: HbA1c TESTING
SHOULD BE PERFORMED AT LEAST
BIANNUALLY IN ALL PATIENTS AND
QUARTERLY FOR PATIENTS WHOSE
THERAPY HAS CHANGED OR WHO ARE NOT
MEETING TREATMENT GOALS
B( l o w ) .
RECOMMENDATION: HbA1c MAY BE USED
FOR THE DIAGNOSIS OF DIABETES, WITH
VALUES ‡6.5% BEING DIAGNOSTIC. AN
NGSP-CERTIFIED METHOD SHOULD BE
PERFORMED IN AN ACCREDITED
LABORATORY. ANALOGOUS TO ITS USE IN
THE MANAGEMENT OF DIABETES,
FACTORS THAT INTERFERE WITH OR
ADVERSELY AFFECT THE HbA1c ASSAY
WILL PRECLUDE ITS USE IN DIAGNOSIS
A( m o d e r a t e ) .
RECOMMENDATION: POINT-OF-CARE
HbA1c ASSAYS ARE NOT SUFFICIENTLY
ACCURATE TO USE FOR THE DIAGNOSIS
OF DIABETES
B (moderate).
RECOMMENDATION: TREATMENT GOALS
SHOULD BE BASED ON ADA
RECOMMENDATIONS, WHICH INCLUDE
GENERALLY MAINTAINING HbA1c
CONCENTRATIONS AT ,7% AND
MORE-STRINGENT GOALS IN SELECTED
INDIVIDUAL PATIENTS IF THEY CAN BE
ACHIEVED WITHOUT SIGNIFICANT
HYPOGLYCEMIA OR OTHER ADVERSE
TREATMENT EFFECTS. SOMEWHAT
HIGHER INTERVALS ARE RECOMMENDED
FOR CHILDREN AND ADOLESCENTS AND
MAY BE APPROPRIATE FOR PATIENTS WITH
A LIMITED LIFE EXPECTANCY, EXTENSIVE
COMORBID ILLNESSES, A HISTORY OF
SEVERE HYPOGLYCEMIA, OR ADVANCED
COMPLICATIONS (NOTE THAT THESE
V A L U E SA R EA P P L I C A B L EO N L YI FT H E
NGSP HAS CERTIFIED THE ASSAY METHOD
AS TRACEABLE TO THE DCCT REFERENCE)
A (high).
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thelack ofstandardizationhasbeenama-
jor barrier. With improved standardiza-
tion through the NGSP and the IFCC,
and new data demonstrating the associa-
tion between HbA1c concentrations and
the risk for retinopathy, the International
Expert Committee recommended the use
ofHbA1cinthediagnosisofdiabetes(20).
In making its recommendation,the Com-
mittee also considered several technical
advantages of HbA1c testing compared
with glucose testing, such as its preana-
lytical stability and decreased biological
variation. Finally, the clinical conve-
nience of the HbA1cassay, which requires
no patient fasting or tolerance tests, com-
pared with glucose-based diagnosis, con-
vinced the Committee to recommend
HbA1c testing for diagnosis. A value
$6.5% (48 mmol/mol) was considered
diagnostic on the basis of the observed
relationship with retinopathy. For
diagnosis, a positive test result [$6.5%
(48 mmol/mol)] should be conﬁrmed
with a repeat assay. The ADA indicates
that although either an HbA1c assay or a
glucose assay (FPGorOGTT)canbeused
as the conﬁrmatory test, repeating the
same test is preferred (93). The frequency
of HbA1c testing for diagnosis has not
been established, but guidelines similar
to those for glucose-based testing seem
appropriate. Only NGSP-certiﬁed HbA1c
methods should be used to diagnose (or
screen for) diabetes. The ADA cautions
that point-of-care devices for measuring
HbA1c should not be used for diagnosis
(93). Although several point-of-care
HbA1c assays are NGSP certiﬁed, the test
iswaivedintheU.S.,andproﬁciencytest-
ing is not necessary. Therefore, no objec-
tive information is available concerning
their performance in the hands of those
whomeasureHbA1cinpatientsamples. A
recent evaluation revealed that few point-
of-care devices that measure HbA1c met
acceptable analytical performance criteria
(254). Absent objective—and ongoing—
documentation of performance with ac-
curacy-based proﬁciency testing that
uses whole blood (or other suitable mate-
rial thatis freefrommatrix effects),point-
of-care HbA1c devices should not be used
for diabetes diagnosis or screening.
The ADA has endorsed the use of HbA1c
for the diagnosis of diabetes (Table 4)
(21), as have The Endocrine Society
(255)andthe WHO.The American Asso-
ciation of Clinical Endocrinologists sup-
ports it in a more limited fashion. Other
international organizations, including
the IDF, are considering HbA1c testing
for diabetes diagnosis and screening.
Note that glucose-based testing for diag-
nosis remains valid. Analogous to the
concept of impaired fasting glucose
andimpairedglucosetolerance,individ-
uals with HbA1c values between 5.7%
and 6.4% (39 and 46 mmol/mol) should
be considered at high risk for future di-
abetes and should be counseled about
effective measures to reduce their risk
(93).
B. Use of other glycated proteins, in-
cluding advanced glycation end prod-
ucts, for routine management of
diabetes. Further studies are needed to de-
termine whether other glycated proteins,
such as fructosamine or glycated serum al-
bumin,areclinicallyusefulforroutinemon-
itoring of patients’ glycemic status. Further
studiesarealsoneededtodetermineifmeas-
urements of advanced glycation end prod-
ucts are clinically useful as predictors of risk
for chronic diabetes complications (256).
OnlyonestudyofasubsetofDCCTpatients
evaluated advanced glycation end products
in dermal collagen obtained with skin biop-
sies. Interestingly, the concentration of ad-
vanced glycation end products in dermal
collagen correlated more strongly with the
presence of complications than the mean
HbA1c values (257). The clinical role of
such measurements remains undeﬁned.
Similarly, the role of noninvasive methods
thatuse light tomeasure glycationtransder-
mally is undeﬁned.
C. Global harmonization of HbA1c
testing and uniform reporting of re-
sults. As noted above, the NGSP has
largely succeeded in standardizing the
GHbassayacrossmethodsandlaborato-
ries. Furthermore, the IFCC standardi-
zation, which provides a chemically
discrete standard, is being implemented
worldwide. The reportingrecommenda-
tions(223)needtobeimplementedwith
the education of healthcare providers
and patients. Some believe that report-
ing eAG should complement the current
reporting in NGSP/DCCT-aligned units
(percentages) and the new IFCC results
(millimoles per mole), because the eAG
resultswillbeinthesameunits(millimoles
per liter or milligrams per deciliter) as
patients’ self-monitoring. Educational
campaigns will be necessary, however,
to ensure clear understanding of this
assay, which is central to diabetes man-
agement.
GENETIC MARKERS
1. Use
A. Diagnosis/screening
1. Type 1 diabetes. Genetic markers are
currently of limited clinical value in eval-
uating and managing patients with diabe-
tes; however, mutational analysis is
rapidly emerging for classifying diabetes
in the neonate (258–260) and in young
patientswithadominantfamilyhistoryof
diabetes, often referred to as “maturity-
onset diabetes of the young” (MODY)
(261). Type 1 or autoimmune diabetes
is strongly associated with HLA-DR (ma-
jor histocompatibility complex, class II,
DR) and HLA-DQ (major histocompatibility
complex, class II, DQ) genes. HLA-DQA1
and HLA-DQB1 genotyping can be useful
to indicate the absolute risk of diabetes.
The HLA DQA1*0301–DQB1*0302 and
DQA1*0501–DQB1*0201 haplotypes,
alone or in combination, may account
for up to 90% of children and young
adults with type 1 diabetes (262). These
two haplotypes may be present in 30%–
40% of a Caucasian population, and HLA
is therefore necessary but not sufﬁcient
for disease. The HLA-DQ and HLA-DR ge-
neticfactorsarebyfarthemostimportant
determinants of type 1 diabetes risk
(263). HLA typing may be used in com-
bination with islet autoantibody analyses
to exclude type 1 diabetes in assisting
in the diagnosis of genetic forms of dia-
betes.
Asindicatedbelow,HLA-DR/DQtyp-
ing can be useful to indicate a modiﬁed
risk of type 1 diabetes in persons positive
for islet cell autoantibodies, because pro-
tective alleles do not prevent the appear-
ance of islet cell autoantibodies (most
often as single autoantibodies) but may
delay the onset of clinical diabetes. Typ-
ing of the class II major histocompati-
bility antigens or HLA-DRB1, -DQA1,
and -DQB1 is not diagnostic for type 1
RECOMMENDATION: ROUTINE
MEASUREMENT OF GENETIC MARKERS IS
NOT OF VALUE AT THIS TIME FOR THE
DIAGNOSIS OR MANAGEMENT OF
PATIENTS WITH TYPE 1 DIABETES. FOR
SELECTED DIABETIC SYNDROMES,
INCLUDING NEONATAL DIABETES,
VALUABLE INFORMATION CAN BE
OBTAINED WITH DEFINITION OF
DIABETES-ASSOCIATED MUTATIONS
A( m o d e r a t e ) .
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tibility, however, whereas others provide
signiﬁcant delay or even protection. Thus,
HLA-DR/DQ typing can be used only to
increaseordecreasetheprobabilityoftype
1 diabetes presentation and cannot be
recommended for routine clinical diagno-
sis or classiﬁcation (264).
The precision in the genetic character-
ization of type 1 diabetes may be extended
by typing for polymorphisms in several
genetic factors identiﬁed in genome-wide
association studies (265). Non-HLA ge-
netic factors include the INS (insulin),
PTPN22 [protein tyrosine phosphatase,
non-receptor type 22 (lymphoid)], and
CTLA4 (cytotoxic T-lymphocyte–associated
protein 4) genes and several others
(263,265). These additional genetic fac-
tors may assist in assigning a probability
for a diagnosis of type 1 diabetes of uncer-
tain etiology (266).
It is possible to screen newborn chil-
dren to identify those at increased risk for
developingtype1diabetes(267–269).This
strategy cannot be recommended until a
proven intervention is available to delay
or prevent the disease (270). There is
some evidence that early diagnosis may
prevent hospitalization for ketoacidosis
andpreserveresidualb-cells(271).Thera-
tionale for the approach is thus discussed
below under Emerging Considerations.
2. Type 2 diabetes. Fewer than 5% of pa-
tients with type 2 diabetes have been re-
solved on a molecular genetic basis, and,
not surprisingly, most of these patients
have an autosomal dominant form of the
disease or very high degrees of insulin
resistance. Type 2 diabetes is a heteroge-
neous polygenic disease with both resis-
tance to the action of insulin and
defective insulin secretion (3,4). Multiple
geneticfactorsinteract withexogenous in-
ﬂuences (e.g., environmental factors such
as obesity) to produce the phenotype.
Identiﬁcationoftheaffectedgenesisthere-
forehighlycomplex.Recentgenome-wide
association studies have identiﬁed .30
genetic factors that increase the risk for
type 2 diabetes (272,273). The risk alleles
intheseloci allhaverelativelysmalleffects
(odds ratios of 1.1 to 1.3), however, and
do not signiﬁcantly enhance our ability to
predict the risk of type 2 diabetes (274).
3. MODY. Detecting mutations in MODY
patients and their relatives is technically
feasible. The reduced costs of sequencing
and emerging new technologies make it
possible to identify mutations and to
properly classify MODY patients on the
basis of speciﬁc mutations. As direct au-
tomated sequencing of genes becomes
standard, it is likely that the detection of
speciﬁc diabetes mutations will become
routine.
B. Monitoring/prognosis. Although ge-
netic screening may provide information
about prognosis and could be useful for
genetic counseling, genotype may not
correlate with the phenotype. In addition
to environmental factors, interactions
among multiple loci for the expression
ofquantitativetraitsmaybeinvolved.Ge-
netic identiﬁcation of a deﬁned MODY
will have value for anticipating the prog-
nosis. Infants with neonatal diabetes due
to a mutation in the KCNJ11 (potassium
inwardly-rectifying channel, subfamily J,
member 11; also known as KIR6.2)g e n e
may be treated with sulfonylurea rather
than with insulin (258,259).
2. Rationale
The HLA system, which has a fundamen-
tal role in the adaptive immune response,
exhibits considerable genetic complexity.
The HLA complex on chromosome 6
contains class I and class II genes that
codeforseveralpolypeptidechains(275).
The major (classic) class I genes are HLA-
A (major histocompatibility complex,
classI,A),HLA-B(majorhistocompatibil-
itycomplex,classI,B),andHLA-C(major
histocompatibility complex, class I, C).
The loci of class II genes are designated
by three letters: the ﬁrst (D) indicates the
class, the second (M, O, P, Q, or R) indi-
cates the family, and the third (A or B)
indicates the chain. Both classes of the
encoded molecules are heterodimers.
Class I molecules consist of an a chain
and b2-microglobulin, and class II mole-
culeshaveaandbchains.Thefunctionof
t h eH L Am o l e c u l e si st op r e s e n ts h o r t
peptides derived from pathogens or auto-
antigens to T cells to initiate the adaptive
immune response (275). Genetic studies
have revealed an association between cer-
tain HLA alleles and autoimmune dis-
eases. These diseases include, but are
not conﬁned to, ankylosing spondylitis,
celiac disease, Addison disease, and type
1diabetes(275).Notonlythediseasebut
also autoantibodies, which are markers
ofthedisease’spathogenesis,areoftenas-
sociatedwithHLA-DRB1,HLA-DQA1,and
HLA-DQB1, indicating that self-peptides
may also be presented to T cells (262).
Genetic testing for syndromic forms
of diabetes is the same as that for the
underlying syndrome itself (1). Such
f o r m so fd i a b e t e sm a yb es e c o n d a r yt o
the obesity associated with Prader–Willi
syndrome, which maps to chromosome
15q, or to the absence of adipose tissue
inherenttotherecessiveSeip–Berardinelli
syndrome of generalized lipodystrophy,
which maps to chromosome 9q34 (1,276).
Morethan60distinctgeneticdisordersare
associated with glucose intolerance or
frank diabetes. Many forms of type 2
diabetes(whichareusuallystronglyfamil-
ial) will probably be understood in de-
ﬁned genetic terms. The complexity of
the genetic factors that contribute to type
2 diabetes risk is substantial (272,273).
Several genetic factors for MODY have
been identiﬁed, and there are large num-
bers of individual mutants. Persons at risk
within MODY pedigrees can be identiﬁed
through genetic means. Depending on the
speciﬁc MODY mutation, the disease can
be mild (e.g., glucokinase mutation) and
not usually associated with long-term
complications of diabetes, or it can be as
severe as typical type 1 diabetes [e.g., he-
patocyte nuclear factor (HNF) mutations]
(277).
Eight different MODYs have been
identiﬁed. MODY-1, -3, -4, -5, -6, and
-7areallcausedbymutationsinthegenes
encoding transcription factors that regu-
late the expression of genes in pancreatic
b-cells. These genes are HNF4A (hepato-
cyte nuclear factor 4, alpha) in MODY-1,
HNF1A(HNF1homeoboxA)inMODY-3,
HNF1B (HNF1 homeobox B) in MODY-5,
PDX1 (pancreatic and duodenal homeobox
1; formerly known as IPF1)i nM O D Y - 4 ,
NEUROD1 (neurogenic differentiation 1;
also known as NeuroD and BETA2)i n
MODY-6, and KLF1 [Kruppel-like factor 1
(erythroid)]inMODY-7.Homozygousmu-
tations of the PDX1 gene have been shown
to lead to pancreatic agenesis, and hetero-
zygous PDX1 mutations have been shown
to cause MODY-4 (276). The modes of ac-
tion of the HNF lesions in MODY are still
not clear. It is likely that mutations in
HNF1A,HNF1B,andHNF4Acausediabetes
because they impair insulin secretion.
MODY-2 is caused by mutations in the
GCK [glucokinase (hexokinase 4)] gene.
The product of the gene is an essential en-
zyme in the glucose-sensing mechanism of
RECOMMENDATION: THERE IS NO ROLE
FOR ROUTINE GENETIC TESTING IN
PATIENTS WITH TYPE 2 DIABETES. THESE
STUDIES SHOULD BE CONFINED TO THE
RESEARCH SETTING AND EVALUATION OF
SPECIFIC SYNDROMES
A( m o d e r a t e ) .
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partial deﬁciencies of insulin secretion.
MODY-8 is due to mutations in the CEL
[carboxyl ester lipase (bile salt-stimulated
lipase)] gene.
3. Analytical considerations
A detailed review of analytical issues will
not be attempted here, because genetic
testing for diabetes outside of a research
setting is currently not recommended for
clinicalcare.SerologicHLAtypingshould
be replaced by molecular methods, be-
cause antibodies with a mixture of spe-
ciﬁcities and cross-reactivities have been
estimated to give inaccurate results in
approximately 15% of typings.
A. Preanalytical. Mutations are detected
by using genomic DNA extracted from pe-
ripheral blood leukocytes. Blood samples
should be drawn into test tubes containing
EDTA, and the DNA should be extracted
within 3 days; longer periods both lower
the yield and degrade the quality of the
DNA obtained. Genomic DNA can be iso-
lated from fresh or frozen whole blood by
lysis, digestion with proteinase K, extrac-
tion with phenol, and then dialysis. The
average yield is 100–200 mg DNA from
10 mL of whole blood. DNA samples are
best kept at 280°C inTris-EDTA solution.
TheseconditionsmaintainDNAsamplein-
tegrity virtually indeﬁnitely.
B. Analytical. Methods for the detection
of mutations vary with the type of muta-
tion. MODY mutations have substitution,
deletion,orinsertionofnucleotidesinthe
coding regions of the genes. These muta-
tions are detected by the PCR. Detailed
protocols for detecting speciﬁcm u t a t i o n s
are beyond the scope of this review.
4. Interpretation
Forscreeningforthepropensityfortype1
diabetes in general populations, HLA-D
genes are the most important, contribut-
ing as much as 50% of familial suscepti-
bility (278). HLA-DQ genes appear to be
central to the HLA-associated risk of type
1 diabetes, albeit HLA-DR genes may be
independently involved [for reviews, see
(279,280)]. The heterodimeric proteins
that are expressed on antigen-presenting
cells, B lymphocytes, platelets, and acti-
vated T cells—but not other somatic
cells—are composed of cis- and trans-
complementated a-a n db-chain hetero-
dimers. Thus, in any individual, four
possible DQ dimers are encoded. Persons
at the highest genetic risk for type 1 di-
abetesarethoseinwhomallfourDQcom-
binations meet this criterion. Thus,
persons heterozygous for HLA DRB1*04–
DQA1*0301–DQB1*0302 and DRB1*
03–DQA1*0501–DQB1*0201 are the
most susceptible, with an absolute lifetime
risk of type 1 diabetes in the general pop-
ulation of about 1 in 12. Persons who are
protected from developing type 1 diabetes
a tay o u n ga g ea r et h o s ew i t hH L A
DRB1*15–DQA1*0201–DQB1*0602
haplotypes in particular (281). Individu-
als with DRB1*11 or 04 who also have
DQB1*0301 are not likely to develop
type 1 diabetes at a young age. HLA-DR
is also involved in susceptibility to type 1
diabetes, in that the B1*0401 and 0405
subtypes of DRB1*04 are susceptible,
whereas the 0403 and 0406 subtypes
arenegativelyassociatedwiththedisease,
even when found in HLA genotypes with
thesusceptibleDQA1*0301–DQB1*0302.
DR molecules are heterodimers also; how-
ever, the DRa chain is invariant in all per-
sons. Additional DRb chains (B3, B4, and
B5) are not important.
Class II MHC molecules are in-
volved in antigen presentation to CD4
helper cells, and the associations out-
lined above are likely to be explained by
defective afﬁnities to islet cell antigenic
peptides, leading to persistence of
T-helper cells that escape thymic abla-
tion. Class I HLA molecules are also
implicated in type 1 diabetes. Multiple
non-HLA loci also contribute to suscep-
tibility to type 1 diabetes (279). For ex-
ample, the variable nucleotide tandem
repeat (VNTR) upstream from the INS
gene on chromosome 11q is useful for
predictingthedevelopmentoftype1di-
abetes, with alleles with the longest
VNTR having protective effects. Typing
newborn infants for both HLA-DR and
HLA-DQ—andtoalesserdegreetheINS
gene—allows prediction of type 1 diabe-
tes to better than 1 in 10 in the general
population. The risk of type 1 diabetes in
HLA-identical siblings of a proband with
type 1 diabetes is 1 in 4, whereas siblings
who have HLA haplotype identity have a 1
in 12 risk and those with no shared haplo-
type have a 1 in 100 risk (280). Genome-
wide association studies have conﬁrmed
that the following non-HLA genetic factors
increasetheriskfortype1diabetes,bothin
ﬁrst-degree relatives of type 1 diabetic pa-
tients and in the general population: INS,
VNTR, CTLA4, PTPN22, and others
(263,265,282,283).
5. Emerging considerations
The sequencing of the human genome and
the formation of consortia have produced
advancesintheidentiﬁcationofthegenetic
bases for both type 1 and type 2 diabetes.
This progress should ultimately lead to
family counseling, prognostic information,
and the selection of optimal treatments
(276,284).
AUTOIMMUNE MARKERS
1. Use
No therapeutic intervention that will pre-
ventdiabeteshasbeenidentiﬁed(279,280).
Therefore, although several islet cell
autoantibodies have been detected in in-
dividuals with type 1 diabetes, their mea-
surement has limited use outside of
clinical studies. Currently, islet cell auto-
antibodies are not used in routine man-
agement of patients with diabetes. This
section focuses on the pragmatic aspects
of clinical laboratory testing for islet cell
autoantibodies.
A. Diagnosis/screening
1. Diagnosis. In type 1 diabetes, the pan-
creatic islet b-cells are destroyed and lost.
In the vast majority of these patients, the
destructionismediatedbyanautoimmune
attack (285). This disease is termed “type
1A”or“immune-mediateddiabetes”(Table
1). Islet cell autoantibodies comprise auto-
antibodies to islet cell cytoplasm (ICA), to
native insulin [referred to as “insulin auto-
antibodies” (IAA) (286)], to the 65-kDa
isoform of glutamic acid decarboxyl-
ase (GAD65A) (287–289), to two insu-
linoma antigen 2 proteins [IA-2A (290)
RECOMMENDATION: ISLET CELL
AUTOANTIBODIES ARE RECOMMENDED
FOR SCREENING NONDIABETIC FAMILY
MEMBERS WHO WISH TO DONATE PART OF
THEIR PANCREAS FOR TRANSPLANTATION
INTO A RELATIVE WITH END-STAGE
TYPE 1 DIABETES
B( l o w ) .
RECOMMENDATION: ISLET CELL
AUTOANTIBODIES ARE NOT
RECOMMENDED FOR ROUTINE DIAGNOSIS
OF DIABETES, BUT STANDARDIZED ISLET
CELL AUTOANTIBODY TESTS MAY BE USED
FOR CLASSIFICATION OF DIABETES IN
ADULTS AND IN PROSPECTIVE STUDIES OF
CHILDREN AT GENETIC RISK FOR TYPE 1
DIABETES AFTER HLA TYPING AT BIRTH
B( l o w ) .
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(291)], and to three variants of zinc
transporter 8 (ZnT8A) (292,293). Auto-
antibody markers of immune destruc-
tion are usually present in 85% to
90% of individuals with type 1 diabetes
when fasting hyperglycemia is initially
detected (1). Autoimmune destruction
of b-cells has multiple genetic predispo-
sitions and is modulated by undeﬁned
environmental inﬂuences. The autoim-
munity may be present for months or
years before the onset of hyperglycemia
and subsequent symptoms of diabetes.
After years of type 1 diabetes, some anti-
bodies fall below detection limits, but
GAD65A usually remains increased.
Patients with type 1A diabetes have a
signiﬁcantly increased risk of other
autoimmune disorders, including celiac
disease, Graves disease, thyroiditis, Ad-
dison disease, and pernicious anemia
(128). As many as 1 in 4 females with
type 1 diabetes have autoimmune thy-
roid disease, whereas 1 in 280 patients
develop adrenal autoantibodies and ad-
renal insufﬁciency. A minority of pa-
tients with type 1 diabetes (type 1B,
idiopathic) have no known etiology
and no evidence of autoimmunity.
Many of these patients are of African or
Asian origin.
2. Screening. Only about 15% of patients
with newly diagnosed type 1 diabetes
have a ﬁrst-degree relative with the dis-
ease (294). The risk of developing type 1
diabetes in relatives of patients with the
disease isapproximately 5%,which is 15-
fold higher than the risk in the general
population (1 in 250–300 lifetime risk).
Screening relatives of type 1 diabetic pa-
tients for islet cell autoantibodies can
identify those at high risk for the dis-
ease; however, as many as 1%–2% of
healthy individuals have a single auto-
antibody against insulin, IA-2, GAD65,
or ZnT8 and are at low risk of develop-
ing type 1 diabetes (295). Because of
the low prevalence of type 1 diabetes
(approximately0.3%inthegeneralpop-
ulation), the positive predictive value
of a single islet cell autoantibody will
be low (280). The presence of multiple
islet cell autoantibodies (IAA, GAD65A,
IA-2A/IA-2bA, or ZnT8A) is associated
with a .90% risk of type 1 diabetes
(292,295,296); however, until cost-
effective screening strategies can be
developed for young children and until
effective intervention therapy to prevent
ordelaytheonsetofthediseasebecomes
available, such testing cannot be recom-
mended outside of a research setting.
Children with certain HLA-DR and/
or HLA-DQB1 chains (*0602/*0603/
*0301) are mostly protected from type
1 diabetes, but not from developing islet
cell autoantibodies (297). Because islet
cell autoantibodies in these individuals
have substantially reduced predictive
signiﬁcance, they are often excluded
from prevention trials.
Approximately 5%–10% of adult
Caucasian patients who present with a
type 2 diabetes phenotype also have islet
cell autoantibodies (298), particularly
GAD65A, which predict insulin depen-
dency. This condition has been termed
“latent autoimmune diabetes of adult-
hood” (LADA) (299), “type 1.5 diabetes”
(300), or “slowly progressive IDDM”
(301). Although GAD65A-positive dia-
betic patients progress faster to absolute
insulinopenia than do antibody-negative
patients, many antibody-negative (type
2) diabetic adults also progress (albeit
more slowly) to insulin dependency
with time. Some of these patients may
show T-cell reactivity to islet cell com-
ponents (300). Islet cell autoantibody
testing in patients with type 2 diabetes
has limited utility, because the institu-
t i o no fi n s u l i nt h e r a p yi sb a s e do ng l u -
cose control.
B. Monitoring/prognosis. No acceptable
therapy has been demonstrated to pro-
long the survival of islet cells once di-
abetes has been diagnosed or to prevent
the clinical onset of diabetes in islet cell
autoantibody–positive individuals (279).
Thus, the use of repeated testing for islet
cell autoantibodies to monitor islet cell
autoimmunity is not clinically useful at
present. In islet cell or pancreas trans-
plantation, the presence or absence of
islet cell autoantibodies may clarify
whether subsequent failure of the trans-
planted islets is due to recurrent auto-
immune disease or to rejection (302).
When a partial pancreas has been trans-
planted from an identical twin or other
HLA-identical sibling, the appearance
of islet cell autoantibodies may raise con-
sideration regarding the use of immuno-
suppressive agents to try to halt the
recurrence of diabetes. Notwithstanding
these theoretical advantages, the value of
this therapeutic strategy has not been es-
tablished.
Some experts have proposed that test-
ing for islet cell autoantibodies may be
useful in the following situations: 1)t o
identify a subset of adults initially thought
to have type 2 diabetes but who have islet
cell autoantibody markers of type 1 diabe-
tes and who progress to insulin depen-
dency (303); 2) to screen nondiabetic
family members who wish todonate a kid-
ney or part of their pancreas for transplan-
tation; 3) to screen women with GDM to
identify those at high risk ofprogression to
type1diabetes;and4)todistinguishtype1
fromtype2diabetesinchildrentoinstitute
insulin therapy at the time of diagnosis
(304,305). For example, some pediatric
diabetologistsnowtreatchildrenthought
to have type 2 diabetes with oral medica-
tions but treat autoantibody-positive
children immediately with insulin. It is
possible, however, to follow patients
who are islet cell autoantibody positive
to the point of metabolic decompensa-
tion and then institute insulin therapy.
The Diabetes Prevention Trial of Type 1
Diabetes (DPT-1) study failed to show a
RECOMMENDATION: SCREENING
PATIENTS WITH TYPE 2 DIABETES FOR
ISLET CELL AUTOANTIBODIES IS NOT
RECOMMENDED AT PRESENT.
STANDARDIZED ISLET CELL
AUTOANTIBODIES ARE TESTED IN
PROSPECTIVE CLINICAL STUDIES OF TYPE
2 DIABETIC PATIENTS TO IDENTIFY
POSSIBLE MECHANISMS OF SECONDARY
FAILURES OF TREATMENT OF TYPE 2
DIABETES
B( l o w ) .
RECOMMENDATION: SCREENING FOR
ISLET CELL AUTOANTIBODIES IN
RELATIVES OF PATIENTS WITH TYPE 1
DIABETES OR IN PERSONS FROM THE
GENERAL POPULATION IS NOT
RECOMMENDED AT PRESENT.
STANDARDIZED ISLET CELL
AUTOANTIBODIES ARE TESTED IN
PROSPECTIVE CLINICAL STUDIES
B( l o w ) .
RECOMMENDATION: THERE IS
CURRENTLY NO ROLE FOR MEASUREMENT
OF ISLET CELL AUTOANTIBODIES IN THE
MONITORING OF PATIENTS IN CLINICAL
PRACTICE. ISLET CELL AUTOANTIBODIES
ARE MEASURED IN RESEARCH PROTOCOLS
AND IN SOME CLINICAL TRIALS AS
SURROGATE END POINTS
B( l o w ) .
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(306).
2. Rationale
The presence of islet cell autoantibodies
suggests that insulin therapy is the most
appropriate therapeutic option, especially
in a young person. Conversely, in children
oryoungpeoplewithoutisletcellautoanti-
bodies, consideration may be given to a
trial of oral agents and lifestyle changes.
There is no unanimity of opinion, but the
presence of islet cell autoantibodies may
alter therapy for subsets of patients, in-
cluding Hispanic and African American
children with a potential diagnosis of non-
autoimmune diabetes, adults with islet cell
autoantibodies but clinically classiﬁed as
type2 diabetic,andchildrenwithtransient
hyperglycemia. The majority of nondia-
betic individuals who have only one auto-
antibody may never develop diabetes.
Although the production of multiple islet
cell autoantibodies is associated with con-
siderablyincreaseddiabetesrisk(295,296),
approximately 20% of individualspresent-
ingwithnew-onsetdiabetesproduceonlya
single autoantibody. Prospective studies of
childrenrevealthatisletcellautoantibodies
may be transient, indicating that an islet
autoantibody may have disappeared prior
to the onset of hyperglycemia or diabetes
symptoms (307).
3. Analytical considerations
For IAAs, a radioisotopic method that
calculates the displaceable insulin radio-
ligandbindingafter the additionofexcess
nonradiolabeled insulin (308) is recom-
mended. Results are reported as positive
when speciﬁc antibody binding exceeds
the 99th percentile or possibly exceeds
t h em e a np l u s2( o r3 )S D sf o rh e a l t h y
persons. Insulin autoantibody binding
hasbeennotednottobenormallydistrib-
uted. Each laboratory needs to assay at
least 100–200 healthy individuals to de-
termine the distribution of binding. An
important caveat concerning IAA mea-
surement is that insulin antibodies
developafter insulintherapy,even inper-
sons who use human insulin. Data from
the Diabetes Autoantibody Standardiza-
tion Program (DASP) demonstrate that
the interlaboratory imprecision for IAA
is inappropriately large (309).
GAD65AandIA-2Aaremeasuredwith
standardized radiobinding assays, which
are performed with
35S-labeled recombi-
nant human GAD65 or IA-2 generated by
coupled in vitro transcription translation
with [
35S]methionine or other
35S- or
3H-labeled amino acids (310). Commer-
cially available methods for GAD65A and
IA-2A are available as a radioimmunoassay
with
125I-labeled GAD65 (truncated at the
N-terminal end to promote solubility) and
IA-2, respectively. In addition, immunoas-
says without radiolabel are commercially
available for both GAD65A and IA-2A.
Major efforts have been made to standard-
ize GAD65A and IA-2A measurements
(309,311). A WHO standard for both
GAD65A and IA-2A has been established,
and GAD65A and IA-2A amounts are ex-
pressed in international units (312). The
binding of labeled autoantigen to autoanti-
bodies is normally distributed. Cutoff val-
ues should be determined from 100–200
serumsamplesobtainedfromhealthyindi-
viduals.GAD65AandIA-2Aresultsshould
be reported as positive when the signal
exceeds the 99th percentile. Comparison
of multiple laboratories worldwide is car-
ried out in the DASP, a proﬁciency-testing
program organized by the CDC under the
auspicesoftheImmunologyofDiabetesSo-
ciety.ThatcommerciallyavailableGAD65A
andIA-2A methodsarealsoparticipatingin
the DASP program demonstrates that it
should be possible not only to harmonize
participating laboratories but also eventu-
ally to standardize GAD65A and IA-2A
(311).
ICAsare measured byindirectimmu-
noﬂuorescence of frozen sections of hu-
man pancreas (313). ICA assays measure
the degree of immunoglobulin binding to
islets, and results are compared with a
WHO standard serum available from the
National Institute of Biological Standards
and Control (312). The results are re-
ported in Juvenile Diabetes Foundation
(JDF) units. Positive results depend on
the study or context in which they are
used, but many laboratories use 10 JDF
unitsmeasuredontwoseparateoccasions
or a single result $20 JDF units as titers
that may indicate a signiﬁcantly increased
risk of type 1 diabetes. The method is
cumbersome and has proved difﬁcult to
standardize. The number of laboratories
that still carry out the ICA assay has de-
creased markedly, and the test is no lon-
ger included in the DASP program.
4. Interpretation
GAD65A may be present in approximately
60%–80% of patients with newly diag-
nosed type 1 diabetes, but the frequency
varies with sex and age. GAD65A is asso-
ciated with HLA DR3–DQA1*0501–
DQB1*0201 in both patients and healthy
individuals. IA-2As may be present
in 40%–50% of patients with newly diag-
nosed type 1 diabetes, but the frequency
is highest in the young. The frequency
decreases with increasing age. IA-2As are
associated with HLA DR4–DQA1*0301–
DQB1*0302. IAA positivity occurs in
.70%–80% of children who develop
type 1 diabetes before 5 years of age but
occurs in ,40% of individuals who de-
velop diabetes after the age of 12 years.
IAAs are associated with HLA DR4–
DQA1*0301–DQB1*0302 and with INS
VNTR (262). ICA is found in about
75%–85% of new-onset patients.
The ICA assay is labor-intensive and
difﬁcult to standardize, and marked in-
terlaboratory variation in sensitivity and
speciﬁcity has been demonstrated in
workshops (284,314). Few clinical labo-
ratories are likely to implement this test.
T h ei m m u n o a s s a y sa r em o r er e p r o d u c -
ible and are amenable to standardization
(309). Measurement ofT-cell reactivity in
peripheral blood is theoretically appeal-
ing, but the imprecision of such assays
precludes their use from a clinical setting
(315,316). Autoantibody positivity (by
deﬁnition) occurs in healthy individuals
despite an absence of a family history of
autoimmune diseases. Islet cell autoanti-
bodies are no exception. If one autoanti-
body is found, the others should be
assayed, because the risk of type 1 diabe-
tes increases if an individual tests positive
for two or more autoantibodies (306).
The following suggestions (279) have
been proposed as a rational approach to
the use of autoantibodies in diabetes: 1)
antibody assays should have a speciﬁcity
.99%; 2)p r o ﬁciency testing should be
documented; 3) multiple autoantibodies
shouldbeassayed;and4)sequentialmea-
surement should be performed. These
strategies will reduce false-positive and
false-negative results.
5. Emerging considerations
Immunoassays for IAA, GAD65A, IA-2A/
IA-2bA, and ZnT8A are now available,
and a panel of these autoantibodies is
RECOMMENDATION: IT IS IMPORTANT
THAT ISLET CELL AUTOANTIBODIES BE
MEASURED ONLY IN AN ACCREDITED
LABORATORY WITH AN ESTABLISHED
QUALITY-CONTROL PROGRAM
AND PARTICIPATION IN A
PROFICIENCY-TESTING PROGRAM
GPP.
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BecauseICAassaysaredifﬁculttostandard-
ize, their use has declined substantially.
It is likely that other islet cell antigens
will be discovered, and such discoveries
could lead to additional diagnostic and
predictive tests for type 1 diabetes. Auto-
antibody screening of dried spots obtained
from ﬁnger-stick blood samples appears
q u i t ef e a s i b l ei nt h ef u t u r e .F o ri n d i v i d u a l s
whoarepositiveforisletcellautoantibodies,
HLA-DR/HLA-DQ genotyping will help de-
ﬁn et h ea b s o l u t er i s ko ft y p e1d i a b e t e s .
Several clinical trials to prevent or
intervene with type 1 diabetes are being
actively pursued (317). Such trials can
now be done with relatives of patients
withtype1diabetesorinthegeneralpop-
ulation on the basis of the islet cell auto-
antibody and HLA-DR/HLA-DQ genotype
status. Risk can be assessed by islet cell
autoantibodies alone, without the need
for evaluating endogenous insulin re-
serves, as was done for the U.S. DPT-1
trial (306).Rates ofislet cellautoantibody
positivity are distinctly lower in the
general population than in relatives of
individuals with type 1 diabetes; conse-
quently, trials with the latter group are
more economical. Potential interven-
tional therapies (for type 1 diabetes) un-
dergoingclinicaltrialsincludeoralinsulin
(317) or nasal insulin (318) given to non-
diabetic (but islet cell autoantibody–
positive) relatives of individuals with
type 1 diabetes or to children with islet
cell autoantibodies and HLA genotypes
conferring increased risk. Phase II clinical
trials with alum-formulated GAD65 have
reported no adverse events and some
preservation of endogenous insulin pro-
duction in GAD65A-positive diabetic pa-
tients (319,320). Additional trials of
other antigen-based immunotherapies,
adjuvants, cytokines, and T-cell acces-
sory molecule–blocking agents are likely
in the future (270). Decreased islet cell
autoimmunitywill beoneimportantout-
come measure of these therapies.
ALBUMINURIA (FORMERLY
MICROALBUMINURIA)—Albu-
minuria (formerly microalbuminuria)
are a well-established cardiovascular risk
marker, in which increases over time to
macroalbuminuria (.300 mg/day) are
associated with kidney disease and an
increased risk for progression to end-
stage renal disease. Annual testing for
albuminuria is recommended by all
majorguidelinesforpatientswithdiabe-
tes and/or kidney disease. To be useful,
semiquantitative or qualitative screening
tests must be shown to be positive in
.95% of patients with albuminuria. Pos-
itiveresultsofsuchtestsmustbeconﬁrmed
by quantitative testing in an accredited
laboratory.
1. Use
A. Diagnosis/screening. Diabetes is as-
sociated with a very high rate of cardio-
vascular events and is the leading cause of
end-stage renal disease in the Western
world(321).Earlydetectionofrisk mark-
ers, such as albumin in the urine (for-
merly termed “microalbuminuria”),
relies on tests for urinary excretion of al-
bumin. Conventional qualitative tests
(chemical strips or “dipsticks”) for albu-
minuria do not detect the small increases
of urinary albumin excretion. For this
purpose, tests to detect albumin concen-
t r a t i o n sa r eu s e d( T a b l e7 )( 3 2 2 –324).
Low levels of albuminuria have been de-
ﬁned by the Joint National Committee
(JNC) 7 and the ADA and have more re-
cently been redeﬁned by the Kidney
Disease: Improving Global Outcomes
Committee (21,325–327) as excretion
of 30–300 mg of albumin/24 h, 20–200
mg/min, or 30–300 mg/mg creatinine
(Table 8) on two of three urine collec-
tions. Recent data, however, suggest
that risk extends below the lower limit
of 20 mg/min (328–330), reinforcing
the notion that this factor is a continuous
variable for cardiovascular risk (331–333).
The JNC 7, the National Kidney
Foundation (NKF), and the ADA all
recommend the use of morning spot
albumin/creatinine measurement for an-
nual quantitative testing for urine albu-
mininadultswithdiabetes(21,326,327).
Individuals should be fasting. The opti-
mal time for spot urine collection is the
early morning, but for minimizing varia-
tion, all collections should be at the same
time of day; the individual preferably
should not have ingested food for at least
2 h (334).
Positive test results represent “albu-
minuria” in these guidelines, correspond-
ingtoproteinexcretionof.300mg/24h,
.200 mg/min, or .300 mg/g creatinine
(Table 8). In these patients, quantitative
measurement of urine albumin excretion
is used in assessing the severity of albu-
minuria and its progression, in planning
treatment, and in determining the impact
of therapy. To properly assess the stage of
kidney disease, the estimated glomerular
ﬁltration rate (eGFR) can be calculated
from the serum creatinine value, age,
sex, and race of the patient (335). An
eGFR of ,60 mL/min, regardless of the
presence of low levels of albuminuria, is
an independent cardiovascular risk factor
(325,327). A urine albumin value of ,30
mg/g creatinine, although considered
“normal,” should be reassessed annually,
because values as low as 10 mg/g creati-
ninehave beenassociated in some studies
with an increased cardiovascular risk. If
thevalueis $30 mg/g creatinine, changes
should be reassessed after 6 to 12 months
Table 7—Review of assays to assess albuminuria
Method Interassay CV Detection limit
Immunonephelometry (Beckman
Coulter Array analyzer)
4.2% at 12.1 mg/L
5.3% at 45 mg/L
2m g / L
Immunoturbidimetry (Dade
Behring turbimeter)
4.1% at 10.6 mg/L
2.2% at 77.9 mg/L
6m g / L
Hemocue (point of care) 2.2% at 77.9 mg/L
4.3% at 82 mg/L
5m g / L
Radioimmunoassay 9.2% at 12.2 mg/dL
4.8% at 33 mg/L
16 mg/L
RECOMMENDATION: ANNUAL TESTING
FOR ALBUMINURIA IN PATIENTS WITHOUT
CLINICAL PROTEINURIA SHOULD BEGIN IN
PUBERTAL OR POSTPUBERTAL
INDIVIDUALS 5 YEARS AFTER DIAGNOSIS
OF TYPE 1 DIABETES AND AT THE TIME OF
DIAGNOSIS OF TYPE 2 DIABETES,
REGARDLESS OF TREATMENT
B (moderate).
RECOMMENDATION: URINE ALBUMIN AT
CONCENTRATIONS ‡30mg/g CREATININE
SHOULD BE CONSIDERED A CONTINUOUS
RISK MARKER FOR CARDIOVASCULAR
EVENTS
B (moderate).
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annually in those who are normotensive
(326). For children with type 1 diabetes,
testing for low levels of albuminuria is
recommended to begin after puberty
and after a diabetes duration of 5 years.
Of note is that most longitudinal cohort
studies have reported signiﬁcant increases
in the prevalence of low levels of albumin-
uriaonlyafterdiabeteshasbeenpresentfor
5 years (326,336).
InthealgorithmsofboththeNKFand
the ADA for urine protein testing (321),
the diagnosis of low levels of albuminuria
requires both the demonstration of in-
creased albumin excretion (as deﬁned
above) on two of three tests repeated at
intervals of 3 to 6 months and the exclu-
sion of conditions that “invalidate” the
test (Fig. 1).
B. Prognosis. Albuminuria values .30
mg/g creatinine [and lower values if the
eGFR is ,60 mL/min (Table 8)] have
prognostic signiﬁcance. Multiple epide-
miologic studies have shown it to be an
independent risk marker for cardiovas-
cular death (325,337,338). In 80% of
patientswithtype1diabetesandlowlevels
of albuminuria, urinary albumin excretion
canincreasebyasmuchas10%–20%/year,
with the development of clinical protein-
uria (.300 mg albumin/day) in 10–15
years in more than half the patients. After
clinical-grade proteinuria occurs, .90%
of patients develop a decreased GFR and,
ultimately,end-stagerenaldisease.Intype
2 diabetes, 20%–40% of patients with
stage A2 albuminuria (Table 8) progress
toovertnephropathy,butby20yearsafter
overt nephropathy, approximately 20%
develop end-stage renal disease. In addi-
tion, patients with diabetes(type1 or type
2) and stage A2 albuminuria are at in-
creased risk for cardiovascular disease.
Of note is that low levels of albuminuria
aloneindicateneither anincreasedriskfor
progression to end-stage kidney disease
nor kidney disease per se; hypertension
needs to be present for the risk of progres-
sion (339,340). Moreover, about 20% of
people progress to end-stage kidney dis-
ease without an increase in low levels of
albuminuria (341). Another factor that in-
dicates progression is an increase in albu-
minuria from stage A2 to A3 over time
despite achievement of blood pressure
goals (342).
C. Monitoring. The roles of routine
urinalysis and albumin measurements
are less clear in patients with stage A2
albuminuria. Some experts have advo-
cated urine protein testing to monitor
treatment, which may include improved
glycemic control, more assiduous control
of hypertension, dietary protein restric-
tion, and therapy with blockers of the
renin angiotensin system (321). Several
factors are known to slow the rate of uri-
nary albumin excretion or to prevent its
development. They include reducing
blood pressure (with a blocker of the renin
angiotensin system as part of the regimen),
glycemic control, and lipid-lowering ther-
apy (45,343–345).
2. Rationale
Early detection of albuminuria allows early
intervention with the goal of reducing
cardiovascular risk and delaying the onset
ofovertdiabeticnephropathy.Thus,itisan
indicator of the need for more intensive
effortstoreducecardiovascularriskfactors.
Albuminuria (stage A2) rarely occurs
with ashortdurationoftype 1 diabetes or
before puberty. Thus, testing is less ur-
gent in these situations. Nevertheless, the
difﬁculty in precisely dating the onset
of type 2 diabetes warrants initiation of
annual testing at the time of diagnosis of
diabetes. Although older patients (age
.75yearsoralifeexpectancy,20years)
may not be at risk for clinically signiﬁcant
nephropathy because of a short projected
life span, they will be at higher cardiovas-
cular risk. In such patients, the role of
treating albuminuria is far from clear.
Published studies have demonstrated
that it is cost-effective to screen all pa-
tients with diabetes and/or kidney disease
for albuminuria (346,347).
3. Analytical considerations
A. Analytical. Analytical goals can be
related to the degree of biological varia-
tion, with less precision required for
analytesthatvary widely. Detectionlimits
and imprecision data are summarized in
Table7.Commerciallyavailablequantita-
tivemethodsforlowlevelsofalbuminuria
have documented detection limits of ap-
proximately 20 mg/L or less. Within-run
imprecisionandday-to-day(total)impre-
cisionarewellwithintheanalyticalgoalof
approximately 15% and are often consid-
erably less. Most, but not all, methods
agreewellandsupportareferenceinterval
of 2–20 mg albumin/mg creatinine (348).
The within-person variation in albu-
min excretion is large in people without
diabetes and is even higher in patients
with diabetes. Howey et al. (349) studied
day-to-day variation, over 3–4 weeks, in
the 24-h albumin excretion, the concen-
tration of albumin, and the albumin–
creatinine ratio. The last two variables
were measured in the 24-h urine sample,
the ﬁrst morning void, and random un-
timed urine collections. In healthy volun-
teers, the lowest within-person CVs were
obtainedfortheconcentrationofalbumin
in the ﬁrst morning void (36%) and for
the albumin–creatinine ratio in that sam-
ple (31%) (349). Multiple studies have Figure 1—Algorithm for urine protein testing.
Table 8—Deﬁnitions of albuminuria
a
Unit of measure
mg/24 h mg/min mg/mg creatinine
Normal ,30 ,20 ,30
High albuminuria (formerly microalbuminuria) 30–300 20–200 30–300
Very high albuminuria
b .300 .200 .300
aFrom the ADA (21).
bAlso called “overt nephropathy.”
RECOMMENDATION: THE ANALYTICAL CV
OF METHODS TO MEASURE LOW LEVELS
OF ALBUMINURIA SHOULD BE ,15%
B (moderate).
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Position Statementevaluated the best procedure to assess al-
buminuria. Most studies have found that
the spot urine albumin–creatinine con-
centration in the ﬁrst morning void,
rather than the 24-h urinary excretion of
a l b u m i no rt h et i m e dc o l l e c t i o n ,i st h e
most practical and reliable technique
(346,350,351).
To keep the analytical CV less than
half the biological CV, an analytical goal
of an 18% CV has been proposed (349).
Alternatively, if the albumin–creatinine
ratio is to be used, one may calculate the
need for a somewhat lower imprecision
(that is, a better precision) to accommo-
date the lower biological CV for the ratio
and the imprecision contributed by the
creatinine measurement. Assuming a CV
of 5% for creatinine measurement, we
calculateagoalof14.7%fortheanalytical
CVforalbuminwhenitisusedtoestimate
the albumin–creatinine ratio. A goal of
15% appears reasonable to accommodate
use of the measured albumin concentra-
tionforcalculatingeitherthetimedexcre-
tion rate or the albumin–creatinine ratio.
Qualitative (or semiquantitative) as-
says have been proposed as screening
tests for low levels of albuminuria. To be
useful, screening tests must have high
detectionrates,i.e.,ahighclinicalsensitivity.
Although many studies have assessed
the ability of reagent strips (“dipstick”
methods) to detect increased albumin con-
centrationsinurine,theimportantquestion
is whetherthemethodcandetectlow levels
of albuminuria, that is, an increased albu-
min excretion rate or its surrogate, an in-
creased albumin–creatinine ratio. We can
ﬁnd no documentation ofany test in which
the sensitivity for detection of an increased
albuminexcretionrate consistently reached
95% in .1 study. For example, in a large
study (352), the sensitivity for detection of
an albumin excretion rate .30 mg/24 h
was 91% when the test was performed
by a single laboratory technician, 86%
when performed by nurses, and 66%
when performed by general practitioners.
In two subsequent studies (353,354), the
sensitivities were 67%–86%. False-positive
results also appear to be common, with
rates as high as 15% (352). Thus, it appears
that at least some of the tests, especially as
used in practice, have the wrong character-
isticsforscreeningbecauseoflowsensitivity
(high false-negative rates), and positive re-
sults must be conﬁrmed by a laboratory
method. Of the available methods, the im-
munoturbidimetric assay is the most reli-
ableandshouldbeconsideredthestandard
for comparison, because it has .95% sen-
sitivity and speciﬁcity to detect very low
levels of albuminuria. Semiquantitative or
qualitative screening tests should be posi-
tive in .95% of patients for the detection
ofalbuminuriatobeuseful for assessment
of cardiovascular risk and progression of
kidney disease. Positive results obtained
with such methodologies must be con-
ﬁrmed by an immunoturbidimetric assay
in an accredited laboratory (355).
Chemical-strip methods are not sen-
sitive when the albumin concentration in
the urine is in the interval of 20–50 mg/L.
Thus, no recommendation can be made
for the use of any speciﬁc screening test.
Dipstick tests for low levels of albumin-
uriacannotberecommendedasareplace-
ment for the quantitative tests.
The available dipstick methods to de-
tect low levels of albuminuria do not
appear to lend themselves to viable screen-
ingstrategies,eitherinthephysician’sofﬁce
or for home testing. Usual screening tests
(e.g., for phenylketonuria) have low false-
negative rates, and thus only positive re-
sultsrequireconﬁrmationbyaquantitative
method. If a screening test has low sensi-
tivity, negative results also must be con-
ﬁrmed, a completely untenable approach.
With semiquantitative tests, it may be pos-
sible (or indeed necessary) to use a cutoff
,20 mg/L to ensure the detection of sam-
ples with albumin values .20 mg/L as
measured by laboratory methods.
Recent studies have compared se-
lected dipstick methods to laboratory
assays. One dipstick was found to have
.95% sensitivity (322,324). One such
study evaluated an ofﬁce-screening test
that uses a monoclonal antibody against
human serum albumin (ImmunoDip;
Genzyme Diagnostics) (322). Screening
182 patient samples with this method
with an albumin–creatinine ratio of $30
mg/mg as positive yielded a sensitivity of
96%, a speciﬁcity of 80%, a positive pre-
dictive value of 66%, and a negative pre-
dictive value of 98%. In a separate study,
165 patients had the HemoCue point-of-
care system for albumin compared with
theClinitek Microalbumin(Siemens) and
Chemstrip Micral (Roche Diagnostics)
tests, as well as with an HPLC assay, for
spot albumin–creatinine ratio measure-
ment (324). Further studies are needed
before the dipstick tests for low levels of
albuminuria can be recommended as re-
placements for the quantitative tests. The
use of qualitative tests at the point of care
is reasonable only when it can be shown
that this approach eliminates quantitative
testinginasizeableproportionofpatients
and detects those patients who have early
renal disease.
B. Preanalytical. Collection of 24-h
samples has disadvantages, speciﬁcally
because many samples are collected
inadequately and because total creatinine
is not routinely checked to evaluate the
adequacy of collection. The albumin–
creatinine ratio is the superior method
to predict renal events in patients with
type 2 diabetes (356). The ratio has a
within-person biological variation similar
to that of the excretion rate and correlates
well with both timed excretion and the
albumin concentration in a ﬁrst morning
RECOMMENDATION: SEMIQUANTITATIVE
OR QUALITATIVE SCREENING TESTS
SHOULD BE POSITIVE IN >95% OF
PATIENTS WITH LOW LEVELS OF
ALBUMINURIA TO BE USEFUL FOR
SCREENING. POSITIVE RESULTS MUST BE
CONFIRMED BY ANALYSIS IN AN
ACCREDITED LABORATORY
GPP.
RECOMMENDATION: CURRENTLY
AVAILABLE DIPSTICK TESTS DO NOT HAVE
ADEQUATE ANALYTICAL SENSITIVITY TO
DETECT LOW LEVELS OF ALBUMINURIA
B (moderate).
RECOMMENDATION: ACCEPTABLE
SAMPLES TO TEST FOR INCREASED
URINARY ALBUMIN EXCRETION ARE TIMED
COLLECTIONS (e.g., 12 OR 24 h) FOR
MEASUREMENT OF THE ALBUMIN
CONCENTRATION AND TIMED OR
UNTIMED SAMPLES FOR MEASUREMENT
OF THE ALBUMIN–CREATININE RATIO
B (moderate).
RECOMMENDATION: THE OPTIMAL TIME
FOR SPOT URINE COLLECTION IS THE
EARLY MORNING. ALL COLLECTIONS
SHOULD BE AT THE SAME TIME OF DAY TO
MINIMIZE VARIATION. THE PATIENT
SHOULD NOT HAVE INGESTED FOOD
WITHIN THE PRECEDING 2 hB U TS H O U L D
BE WELL HYDRATED (i.e., NOT VOLUME
DEPLETED)
GPP.
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Sacks and Associatesvoid of urine (349). For the ratio, a ﬁrst
morningvoidsampleispreferablebecause
thissamplehasalowerwithin-personvar-
iation than the ratio for a random urine
sample taken during the day (349). Al-
though the ratio appears entirely accept-
able for screening, limited data are
available on its use in monitoring the re-
sponse to therapy. Recent post hoc analy-
ses of clinical trials, however, have found
that the albumin–creatinine ratio is a rea-
sonablemethodtoassesschangeovertime
(357). For screening, an untimed sample
for albumin measurement (without creat-
inine) may be considered if one uses a
concentration cutoff that allows high sen-
sitivity for detecting an increased albumin
excretion rate.
Albumin is stable in untreated urine
stored at 4°C or 20°C for at least a week
(358). Neither centrifugation nor ﬁltra-
tion appears necessary before storage at
220°C or 280°C (359). Whether a urine
sample is centrifuged, ﬁltered, or not
treated, the albumin concentration de-
creases by 0.27%/day at 220°C but
shows no decreases over 160 days at
280°C(359).Theurinaryalbuminexcre-
tion rate does not show marked diurnal
variation in diabetes but does so in essen-
tial hypertension (360).
4. Interpretation
A. Nonanalytical sources of variation.
Transient increases in urinary albumin
excretion have been reported with short-
term hyperglycemia, exercise, urinary
tract infections, marked hypertension,
heart failure, acute febrile illness, and
hyperlipidemia (321).
B. Frequency of measurement. The
NKF, ADA, and JNC 7 recommend an-
nual measurement in diabetic patients
with albumin–creatinine ratios ,30
mg/mg. After the documentation of stage
A2 albuminuria (i.e., with results as de-
ﬁned above on two of three tests per-
formed within 3 to 6 months), repeated
testing is reasonable to determine
whether a chosen therapy is effective. It
may also be useful in determining the
rate of disease progression and thus
may support planning for care of end-
stage renal disease. Although the ADA
recommendations suggest that such test-
ing is not generally needed before pu-
berty, testing may be considered on an
individual basis if it appears appropriate
b e c a u s eo fa ne a r l yo n s e to fd i a b e t e s ,
poor control, or a family history of dia-
betic nephropathy. The duration of dia-
betes prior to puberty is reportedly an
important risk factor in this age-group
and thus can be used to support such
testing in individual patients (361).
MISCELLANEOUS
POTENTIALLY IMPORTANT
ANALYTES. I. INSULIN AND
PRECURSORS
1. Use
A. Diagnosis. In the last several years,
interest has increased in the possibility
that measurements of the concentrations
ofplasmainsulinanditsprecursorsmight
be of clinical beneﬁt. In particular, pub-
lished evidence reveals that increased
concentrations of insulin and/or proinsu-
lin in nondiabetic individuals predict the
development of coronary artery disease
(362). Although this possibility may be
scientiﬁcally valid, its clinical value is
questionable. An increased insulin con-
centration is a surrogate marker that can
be used to estimate resistance to insulin-
mediated glucose disposal, and it can
identify individuals at risk for developing
syndrome X, also known as the insulin
resistancesyndromeorthemetabolicsyn-
drome (363). Accurate measurement
ofinsulinsensitivityrequirestheuseofcom-
plexmethods,suchasthehyperinsulinemic
euglycemic clamp technique, which are
generallyconﬁnedtoresearchlaboratories
(364,365). Because of the critical role of
insulin resistance in the pathogenesis of
type 2 diabetes, hyperinsulinemia would
also appear to be a logical risk predictor
for incident type 2 diabetes.
Earlier studies may not have con-
trolled well for glycemic status and other
confounders. More-recent analyses sug-
gest that insulin values do not add signif-
icantly to diabetes risk prediction carried
out with more traditional clinical and
laboratory measurements (366) and that
measures of insulin resistance (that in-
clude insulin measurements) predict the
risk of diabetes or coronary artery disease
only moderately well, with no threshold
effects (367). Consequently, it seems of
greater clinical importance to quantify
theconsequencesoftheinsulinresistance
and hyperinsulinemia (or hyperproinsu-
linemia) rather than the hormone values
themselves,i.e.,bymeasuringbloodpres-
sure, the degree of glucose tolerance, and
plasma lipid/lipoprotein concentrations.
It is these variables that are the focus of
clinical interventions, not plasma insulin
or proinsulin concentrations (366,367).
The clinical utility of measuring
insulin, C-peptide, or proinsulin concen-
trations to help select the best antihyper-
glycemic agent for initial therapy in
patients with type 2 diabetes is a question
that arises from consideration of the
pathophysiology of type 2 diabetes. In
theory, the lower the pretreatment insulin
concentration, the moreappropriate might
be insulin, or an insulin secretagogue, as
the drug of choice to initiate treatment.
Although this line of reasoning may have
RECOMMENDATION: LOW URINE
ALBUMIN CONCENTRATIONS (i.e., ,30
mg/g CREATININE) ARE NOT
ASSOCIATED WITH HIGH
CARDIOVASCULAR RISK IF THE eGFR IS
>60mL ·min
21·(1.73m
2)
21
AND THE
PATIENT IS NORMOTENSIVE. IF THE eGFR
IS ,60 mL · min
21 · (1.73 m
2)
21
AND/OR THE LEVEL OF ALBUMINURIA
IS ‡30 mg/g CREATININE ON A SPOT
URINE SAMPLE, A REPEAT MEASUREMENT
SHOULD BE TAKEN WITHIN THE YEAR
TO ASSESS CHANGE AMONG PEOPLE
WITH HYPERTENSION
A( m o d e r a t e ) .
RECOMMENDATION: THERE IS NO ROLE
FOR ROUTINE TESTING FOR INSULIN,
C-PEPTIDE, OR PROINSULIN IN MOST
PATIENTS WITH DIABETES.
DIFFERENTIATION BETWEEN TYPE 1 AND
TYPE 2 DIABETES MAY BE MADE IN MOST
CASES ON THE BASIS OF THE CLINICAL
PRESENTATION AND THE SUBSEQUENT
COURSE. THESE ASSAYS ARE USEFUL
PRIMARILY FOR RESEARCH PURPOSES.
OCCASIONALLY, C-PEPTIDE
MEASUREMENTS MAY HELP DISTINGUISH
TYPE 1 FROM TYPE 2 DIABETES IN
AMBIGUOUS CASES, SUCH AS PATIENTS
WHO HAVE A TYPE 2 PHENOTYPE BUT
PRESENT IN KETOACIDOSIS
B (moderate).
RECOMMENDATION: THERE IS NO ROLE
FOR MEASUREMENT OF INSULIN
CONCENTRATION IN THE ASSESSMENT OF
CARDIOMETABOLIC RISK, BECAUSE
KNOWLEDGE OF THIS VALUE DOES NOT
ALTER THE MANAGEMENT OF THESE
PATIENTS
B (moderate).
e88 DIABETES CARE, VOLUME 34, JUNE 2011 care.diabetesjournals.org
Position Statementsome intellectual appeal, there is no evi-
dence that measurement of plasma insulin
or proinsulin concentrations will lead to
more efﬁcacious treatment of patients with
type 2 diabetes.
In contrast to the above considera-
tions,measurementofplasmainsulinand
proinsulin concentrations is necessary to
establish the pathogenesis of fasting hy-
poglycemia (368). The diagnosis of an is-
let cell tumor is based on the persistence
ofinappropriatelyincreasedplasmainsu-
lin concentrations in the face of a low
glucoseconcentration.Inaddition,anin-
crease in the ratio of fasting proinsulin to
insulin in patients with hypoglycemia
strongly suggests the presence of an islet
cell tumor. The absence of these associ-
atedchangesinglucose,insulin,andpro-
insulin concentrations in an individual
with fasting hypoglycemia makes the diag-
nosis of an islet cell tumor most unlikely,
and alternative explanations should be
sought for the inability to maintain fasting
euglycemia.
Measurement of the C-peptide re-
sponse to intravenous glucagon can aid
in instances in which it is difﬁcult to
differentiate between the diagnosis of
type 1 and type 2 diabetes (5). Even in
this clinical situation, however, the re-
sponse to drug therapy will provide use-
ful information, and measurement of
C-peptidemaynotbeclinicallynecessary.
Measurement of C-peptide is essential in
the investigation of possible factitious hy-
poglycemia due to surreptitious insulin
administration (369).
In the past, some advocated insulin
assays in the evaluation and management
of patients with the polycystic ovary syn-
drome. Women with this syndrome man-
ifestinsulinresistancebyandrogenexcess,
as well as by abnormalities of carbohydrate
metabolism; both abnormalities may re-
spond to treatment with metformin or
thiazolidinediones. Although clinical tri-
als have generally evaluated insulin re-
sistance by using the hyperinsulinemic
euglycemic clamp, ratios of fasting glu-
cose to insulin, and other modalities, the
optimal laboratory evaluation of these
patients in routine clinical care has not
been clearly deﬁned. It is unclear whether
assessing insulin resistance through insulin
measurement has any advantage over
assessment of physical signs of insulin
resistance (BMI, presence of acanthosis
nigricans), and routine measurements
of insulin are not recommended by the
American College of Obstetrics and Gy-
necology (370).
2. Analytical considerations
Although it has been assayed for .40
years, there is no standardized method
available to measure serum insulin
(371).Attemptstoharmonizeinsulinas-
says with commercial insulin reagent
sets have produced greatly discordant
results (372). Recently, an insulin stan-
dardization workgroup of the ADA, in
conjunction with the National Institute
of Diabetes and Digestive and Kidney
Diseases, the CDC, and the European
Association for the Study of Diabetes,
called forharmonizationofinsulinassay
resultsthroughtraceabilitytoanisotope-
dilution liquid chromatography–tandom
massspectrometryreference(373).TheIn-
sulin Standardization Workgroup called
for harmonization of the insulin assay to
encourage the development of measures
of insulin sensitivity and secretion that
will be practical for clinical care (374).
Analogous to insulin, considerable impre-
cision among laboratories has also been
observed for measurement of C-peptide.
A comparison of 15 laboratories that
used nine different routine C-peptide as-
say methods, found within- and between-
run CVs as high as .10% and 18%,
respectively (375). A committee has been
established under the auspices of the CDC
to harmonize C-peptide analysis.
Measurements of proinsulin and C-
peptide are accomplished by immuno-
metric methods. Proinsulin reference
intervals are dependent on methodology,
and each laboratory should establish its
own reference interval. Although it has
been suggested by some, insulin mea-
surement should not be used in an OGTT
to diagnose diabetes. In the case of C-
peptide, there is a discrepancy in reliabil-
ity because of variable speciﬁcity among
antisera, lack of standardization of C-
peptide calibration, and variable cross-
reactivity with proinsulin. Of note is the
requirement of the U.S. Centers for Medi-
care and Medicaid Services that Medicare
patients have C-peptide measured in order
tobeeligibleforcoverageofinsulinpumps.
Initially, the requirement was that the
C-peptide concentration be #0.5 ng/mL;
however, because of the noncomparability
ofresultsfromdifferentassays,whichledto
denial of payment for some patients with
values .0.5 ng/mL, the requirement now
states that the C-peptide concentration
should be #110% of the lower limit of
the reference interval of the laboratory’s
measurement method (376).
MISCELLANEOUS
POTENTIALLY IMPORTANT
ANALYTES. II.
INSULIN ANTIBODIES
Given sufﬁciently sensitive techniques,
insulin antibodies can be detected in any
patient being treated with exogenous in-
sulin (371). In the vast majority of pa-
tients, the titer of insulin antibodies is
low, and their presence is of no clinical
signiﬁcance. Very low values are seen in
patients treated exclusively with human
recombinant insulin (377). On occasion,
however, the titer of insulin antibodies in
the circulation can be quite high and as-
sociated with a dramatic resistance to the
ability of exogenous insulin to lower
plasma glucose concentrations. This clin-
ical situation is quite rare, it usually oc-
curs in insulin-treated patients with type
2 diabetes, and the cause-and-effect rela-
tionships between the magnitude of the
increase in insulin antibodies and the de-
gree of insulin resistance are unclear.
There are several therapeutic approaches
for treating these patients, and a quantita-
tive estimate of the concentration of cir-
culating insulin antibodies does not
appear to be of signiﬁcant beneﬁt.
The prior version of these guidelines
(14) contained short sections on amylin
and leptin, both of which were the focus
of active clinical studies. The evidence
that has accumulated in the last 7 to 8
years has failed to identify any clinical
value in measuring these analytes in pa-
tients with diabetes. Similarly, although
cardiovascular disease is the major cause
of mortality for persons with diabetes, no
evidence supports the measurement of
nontraditional cardiovascular risk factors
RECOMMENDATION: BECAUSE CURRENT
MEASURES OF INSULIN ARE POORLY
HARMONIZED, AS T A N D A R D I Z E DI N S U L I N
ASSAY SHOULD BE DEVELOPED TO
ENCOURAGE THE DEVELOPMENT OF
MEASURES OF INSULIN SENSITIVITY THAT
WILL BE PRACTICAL FOR CLINICAL CARE
GPP.
RECOMMENDATION: THERE IS NO
PUBLISHED EVIDENCE TO SUPPORT THE
USE OF INSULIN ANTIBODY TESTING FOR
ROUTINE CARE OF PATIENTS WITH
DIABETES
C (very low).
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Sacks and Associatesfor routine assessment of risk in patients
with diabetes. These sections have, there-
fore, been removed.
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